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INVESTIGATION OF INTERLEUKIN-10 (IL-10) PRODUCTION  
FROM HELICOBACTER-ACTIVATED IL-10+ B CELLS ON MOLECULAR 
LEVEL 
 
SUMMARY 
Helicobacter pylori (H.pylori) is a gram-negative, spiral-shaped, microaerophilic 
bacterium that is defined to be a common risk factor for development of gastric 
malignancies that may lead to gastric cancer. Approximately 50% of the world’s 
population is infected with H.pylori. The prevalence of H.pylori infection goes up to 
80% in developing countries. Although majority of world population is infected, only 
20% of infected individuals may develop  peptic ulcer, MALT (mucosa-associated 
lymphoid tissue) lymphoma and gastric adenocarcinoma. Majority of infected 
individuals are asymptomatic. Anti-inflammatory cytokine interleukin-10 (IL-10) 
represses immune response against pathogens and attenuates damage to host which 
may occur due to excessive inflammation. B and T cells are known to have regulatory 
subtypes. Recent researches indicate that IL-10 producing B cells have suppressive 
and immune regulatory role in mouse models of Helicobacter felis infection. 
Helicobacter felis (H.felis) is closely related to Helicobacter pylori. Helicobacter felis 
is widely used in animal models since it has higher immunogenicity for mice.  
The signals received through ligands binding to their cognate receptors on cell 
surface are relayed by various intracellular signaling routes. The signal relayed 
through intracellular signaling pathways elicits a cellular response proper for the 
stimuli. It has been recently reported that IL-10 is produced and secreted through 
Toll-like receptor 2 (TLR2) signaling in Helicobacter-activated IL-10 producing B 
cells. It is known that TLR-mediated IL-10 secretion is maintained through MAPK 
(mitogen-activated protein kinase), PI3K (Phosphatidylinositol-4,5-bisphosphate 3-
kinase) and NF-κB  (Nuclear   factor  kappa-light-chain-enhancer of activated B cells) 
signaling pathways in macrophages and dendritic cells, antigen presenting cells of the 
innate immune system. Fundamental intracellular signaling pathways that are 
investigated in this study are therefore MAPK, PI3K and NF-κB  signal  transduction  
pathways.  
There are many proteins that that part in intracellular signal transduction. Proteins 
that enable phosphorylation of themselves and other proteins by enzymatic reactions 
are termed as kinases. Aforementioned intracellular signaling pathways require 
activity of many kinases. These pathways induce sequential phosphorylation of 
protein kinases which leads to activation of various transcription factors that will 
translocate into nucleus and initiate transcription of genes related to proper cellular 
response to the stimuli. Phosphorylation of two protein kinases of MAPK signaling 
pathway, p38 MAPK and p44/42 MAPK (ERK-1/2) were shown to be required for 
induction of IL-10 production. PI3K signaling pathway requires phosphorylation of 
Akt. These separate pathways induce the phosphorylation, thereby activation of 
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downstream signaling molecules such as CREB (cAMP response element-binding 
protein) which leads to IL-10 expression in macrophages. Phosphorylation of each 
element in intracellular signaling pathway is generally closely related with their 
activation status. Therefore, activation of MAPK and PI3K signaling pathways can be 
determined by investigating phosphorylation status of p38 MAPK, ERK-1/2, Akt and 
CREB. For activation check on canonical pathway of NF-κB,  phosphorylation  of  p65  
subunit can be examined.   
Although intracellular signaling pathways that play a role in IL-10 production from 
immune cells such as macrophages, dendritic cells or T cells have been characterized, 
intrinsic signal transduction pathways responsible for expression and secretion of IL-
10 in Helicobacter-activated B cells have been ill-defined. It was recently reported 
that Helicobacter-activated IL-10+ B cells have important contribution to prevention 
of Helicobacter-associated gastric pathology. Identification of signaling pathways 
that take part in induction of IL-10 production from Helicobacter-activated IL-10+ B 
cells will pave the way for immune therapeutic researches that target these cells. For 
this reason, the focus of this study was identification of intracellular signaling 
pathways responsible for induction of IL-10 production from TLR2-stimulated B 
cells. For that purpose, splenic naïve  B  cells of C57BL/6 mice were stimulated with 
H.felis sonicate in order to induce IL-10 production and secretion. Then, H.felis 
sonicate-stimulated B cells were separated magnetically according to their IL-10 
production capacities. Magnetic separation resulted in two fractions: Helicobacter-
activated IL-10- B cells and IL-10+ B cells.  
Protein samples of murine naïve   B   cells,   Helicobacter felis sonicate-stimulated B 
cells, Helicobacter-activated IL-10- B cells and IL-10+ B cells were investigated for 
phosphorylation status of specific kinases which constitute significant junctions in 
MAPK, PI3K and NF-κB signaling pathways. Phosphorylation levels were 
determined via Western Blotting by making use of specific antibodies that recognize 
total- and phosphorylated forms of related signaling molecules. For investigation of 
NF-κB pathway, phosphorylation of p65 subunit was determined via signaling node 
sandwich ELISA method.  
Following determination of phosphorylation status, the changes in IL-10 secretion 
from Helicobacter-activated B cells upon blocking of examined signaling pathways 
with specific inhibitors that inhibit activation of related kinases was investigated in 
order to identify the role of blocked signaling pathway on IL-10 production and 
secretion. For this purpose, p38 MAPK and ERK-1/2 modules of MAPK signaling 
pathway, PI3K signaling pathway and canonical pathway of NF-κB  were  blocked  in  
murine naïve  B  cells  and H.felis sonicate-stimulated B cells by chemical inhibitors. 
Then, the amount of secreted IL-10 culture supernatants was determined 
quantitatively by IL-10 ELISA.  
The results of this study regarding identification of intracellular pathways taking part 
in induction of IL-10 production and secretion from Helicobacter-activated IL-10+ B 
cells revealed that ERK-1/2 got significantly more phosphorylated in Helicobacter-
activated IL-10+ B cells following a comparison between Helicobacter-activated IL-
10- B and IL-10+ B cells. On the other hand, phosphorylation levels of both p38 
MAPK and Akt were found to be significantly elevated in Helicobacter-activated IL-
10- B cells. No significant change in phosphorylation status of p65 subunit of NF-κB  
canonical signaling pathway was determined. These findings suggest a more 
prominent role for ERK-1/2 activation in induction of IL-10 production from 
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Helicobacter-activated B cells. Moreover, investigation regarding the effect of 
blocked signaling pathways on IL-10 secretion showed that only inhibition of signal 
transduction through ERK-1/2 module of MAPK signaling pathway resulted in 
significant reduction of secreted IL-10 from Helicobacter-activated B cells. This 
finding supports the hypothesis on the prominent role of ERK-1/2 signaling in IL-10 
production from Helicobacter-activated B cells. Significance of this research 
underlies in its contribution to the understanding of unexplored intrinsic signal 
transduction pathways of TLR2-mediated IL-10 production from B cells and the 
involvement of ERK-1/2 module of MAPK pathway in induction of IL-10 production 
from Helicobacter-activated B cells.  
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HELİKOBAKTER-AKTİVE  İNTERLÖKİN-10+ (IL-10+) B 
HÜCRELERİNDEN  IL-10  ÜRETİMİNİN  MOLEKÜLER  DÜZEYDE  
İNCELENMESİ 
 
ÖZET 
 
Helikobakter pilori (H.pilori) gram-negatif,   spiral   yapıda,  mikroaerofilik  bir  bakteri  
olmakla beraber gastritten mide kanserine kadar uazanan gastrik patolojilerin temel 
risk   faktörü   olarak   tanımlanmıştır.   Dünya   nüfusunun   yaklaşık   %50’si   H.pilori ile 
enefektedir. Bu oran  gelişmekte  olan  ülkelerde  %80’e  çıkabilmektedir. Ancak  dünya  
genelinde   enfekte   olan   kişi   sayısı   oldukça   fazla   olmasına   karşın, enfekte bireylerin 
yalnızca  %  20’sinde  ise  peptik  ülser,  MALT  lenfoma  ve  mide  kanseri  gibi  patolojiler  
görülmektedir.   Enfekte   bireylerin   büyük   bir   kısmı   herhangi   bir   semptom  
göstermemektedir.   İnterlökin-10 (IL-10)   patojenlere   karşı   oluşan   immün   cevabı  
baskılaması   ve   dolayısıyla   patojene   karşı   oluşacak   immün   cevap   esnasında  
üretilebilecek  pro-inflamatuvar  sitokinlerin  aşırı  inflamasyon  nedeniyle  konağa  zarar  
vermesini engellemesi ile anti-inflamatuvar   özellik   gösteren   bir   sitokindir. B ve T 
hücrelerinin   IL-10   üreten   regülatör   alt   tipleri   olduğu   bilinmektedir.   Güncel  
araştırmalar,  Helikobakter felis (H.felis) enfeksiyonu fare modellerinde IL-10  üreten  
B   hücrelerinin   immün   cevabı   baskılayıcı   ve   düzenleyici   rolü   olduğunu   ortaya  
koymuştur.   H.felis, H.pilori ile aynı   aileden   gelmektedir   ancak   farelerde   immün  
cevap  oluşturma  olasılığı  daha  yüsek  olduğundan  fare  modellerinde  kullanılmaktadır. 
Reseptörlere   bağlanan   ligandlar   aracılığı   ile   alınan   sinyaller   hücre   içinde   çeşitli  
yollardan   iletilmektedir.   Hücre   içi   sinyal   yolakları   tarafından   iletilen   uyarı,   sinyale  
uygun   bir   cevap   verilmesini   sağlamaktadır.   IL-10   üreten   Helikobakter-aktive B 
hücrelerinden   IL-10   salınımının   Toll-benzeri   reseptör   2   (TLR2)   aracılığıyla  
sağlandığı  yakın  zaman  önce  gösterilmiştir.  Doğal  bağışıklık  sisteminin  antijen  sunan  
hücreleri   olan   makrofajlar   ve   dendritik   hücrelerden   TLR-uyarımı   ile   IL-10 
üretilmektedir.   Bu   hücrelerden   IL-10   üretim   ve   salınımının   mitojen aktive protein 
kinaz (MAPK), fosfatidilinositol-3 kinaz (PI3K) ve nükleer  faktör-kappa B (NF-κB) 
sinyal   yolakları   aracılığıyla   olduğu   bilinmektedir. Dolayısıyla,   bu   çalışmada  
incelenen   önemli   hücre   içi   sinyal   iletim   yolları   MAPK,   PI3K   ve   NF-κB   sinyal  
yolaklarıdır. 
Hücre   içi   sinyal   iletiminde  bir   çok  protein   görev  almaktadır.  Enzimatik reaksiyonla 
kendinin   veya   başka   proteinlerin   fosforilasyonunu   sağlayan   proteinler   kinaz   adını  
almaktadır.   Bahsedilen   sinyal   iletim   mekanizmaları   bir   çok   kinazın   aktivitesini  
gerektirmektedir.   İlgili   yolaklar   bir   dizi   kinazın   fosforilasyonunun   ardından   sinyal 
yolağını   tetikleyen   sinyale   uygun   immün   cevap   oluşturmak   amacıyla   nükleusa  
gidecek  ve   ilgili  gen  bölgesine  bağlanarak   immün  cevapla   ilintili  gen  veya  genlerin  
transkripsiyonunu  sağlayacak  çeşitli  transkripsiyon  faktörlerinin  aktivasyonuna  neden  
olurlar. MAPK  sinyal  kaskadında  IL-10  üretiminde  rol  oynadığı  gösterilen  iki  kinaz  
p38 MAPK ve p44/42 MAPK (ERK-1/2)’dır.   PI3K   sinyal   yolağında   sinyal   iletimi  
Akt  kinazın   fosforilasyonu  aracılığıyla  gerçekleşmektedir.  CREB  (siklik AMP tepki 
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elemanı   bağlayıcı   protein) ise bahsedilen   sinyal   yolakları   tarafından   aktive   olduğu  
bilinen ve makrofajların   IL-10 transkripsiyonunda aktif rol alan bir transkripsiyon 
faktörüdür.  Hücre  içi  sinyal  yolaklarında  bir  sinyal  molekülünün  fosforilasyonu  genel  
olarak aktivasyonu anlamına   gelmektedir.  Diğer   bir   deyişle  MAPK  ve   PI3K   sinyal  
yolaklarının   aktivasyonu   p38   MAPK,   ERK-1/2, Akt ve CREB fosforilasyonuna 
bakılarak  tayin  edilebilir.  NF-κB  klasik  sinyal  yolağında  ise  p65  sinyal  molekülünün  
fosforilasyonu aktivasyon ile ilintilidir.  
Makrofajlar,  dendritik  hücreler  ve  T  hücreleri  gibi  bağışıklık  sistemi  hücrelerinde  IL-
10   üretiminde   rol   oynayan   hücre   içi   sinyal   yolakları   karakterize   edilmiş   olmasına  
karşın,  TLR2-aracılığı  ile  aktive  olan  B  hücrelerinde  IL-10  üretimini  sağlayan  hücre  
içi   sinyal   yolakları   bilinmemektedir.   Helikobakter-aktive IL-10+ B   hücrelerinin  
Helikobakter-aracılıklı   mide   patolojisini   önlemede   önemli   bir   katkısı   olduğu  
bilinmektedir. Helikobakter-aktive IL-10+ B   hücrelerinden   IL-10   üretiminde rol 
oynayan sinyal iletim  yolaklarının  tespiti,  ilgili  hücrelerin  kullanılacağı  immün  tedavi  
araştırmalarına  da  zemin  hazırlaması  bakımından  önem  teşkil  etmektedir. Bu nedenle, 
bu   çalışmanın   odak   noktası   B   hücrelerinin   TLR2-uyarımı   ile   IL-10   üretmesini  
sağlayan   hücre   içi   sinyal   yolaklarının   tespit   edilmesidir.   Bu   amaçla,   C57BL/6 
dalağından   elde   edilen   naif   B   hücreleri   H.felis sonikatı   ile   uyarılmış   ve   ilgili  
hücrelerden   TLR2-aracılıklı   IL-10   üretimi   ve   salınımı   gerçekleşmesi   sağlanmıştır.  
Ardından  H.felis sonikatı   ile  uyarılmış  B  hücreleri   IL-10  üretme  kapasitelerine  göre  
manyetik   yöntemle   ayrılmış   ve   IL-10 negatif (IL-10- B   hücreleri)   ve   IL-10 pozitif 
(IL-10+ B  hücreleri)  fraksiyonlar  elde  edilmiştir.     
Fare-kaynaklı   naif   B   hücreleri,   H.felis sonikatı   ile   uyarılmış   B   hücreleri,  
Helikobakter-aktive IL-10- B ve IL-10+ B  hücrelerinden  elde  edilen  protein  örnekleri  
MAPK, PI3K ve NF-κB   yolaklarında   kilit   rol   oynayan   sinyal   moleküllerinin    
fosforilasyonu   açısından   incelenmiştir.   İlgili   sinyal   moleküllerinin   fosforilasyonları  
total ve fosforile   formlarını   tanımak   için   özelleşmiş   antikorlar   kullanılarak  Western  
blotlama   yöntemi   ile   tayin   edilmiştir.   NF-κB   klasik   sinyal   yolağında   önemli   rol  
oynayan   p65   sinyal   molekülünün   fosforilasyonu   ise   sinyal   yolağı   protein   ELISA  
yöntemi  ile  tayin  edilmiştir. 
Fosforilasyon   tayininin   ardından,   hücre   içi   yolaklarda   görev   alan   kinazların  
aktivitesini   baskılayan   spesifik   inhibitörler   yardımıyla   ilgili   yolakların   bloklanması  
sonucu Helikobakter-aktive B   hücrelerinden   IL-10   salınımındaki   değişim  
incelenmiştir.   Bu   sayede,   baskılanan   sinyal   yolağının   IL-10   üretimindeki   etkisinin  
anlaşılması   amaçlanmıştır.   Bu   amaçla,   fare-kaynaklı   naif   B   hücreleri   ve   H.felis 
sonikatı  ile  uyarılmış  B  hücrelerinin MAPK  sinyal  yolağının  p38  MAPK  modülü  ve    
ERK-1/2 modülü,   PI3K   sinyal   yolağı   ve   NF-κB   klasik sinyal yolakları   kimyasal  
inhibitörler  kullanılarak  bloklanmıştır. Ardından  hücre  üst-fazları  toplanmış  ve  hücre  
üst-fazlarındaki   IL-10   miktarı   IL-10   ELISA   yöntemi   uygulanarak   kantitatif   olarak  
belirlenmiştir.   
Helikobakter-aktive IL-10+ B  hücrelerinden   IL-10  üretimini  ve  salınmasını  sağlayan  
hücre   içi   sinyal   yolaklarının   incelenmesi   ve   belirlenmesini   amaçlayan   çalışmanın  
sonucunda elde edilen verilere gore Helikobakter-aktive IL-10- B ve IL-10+ B  hücre  
örnekleri   arasında   yapılan   karşılaştırma   sonrasında   ERK-1/2 proteinlerinin 
Helikobakter-aktive IL-10+ B   hücrelerinde   anlamlı   düzeyde   daha fazla fosforile 
olduğu   görülmüştür.   İncelenen   diğer   kinazların   (p38   MAPK   ve   Akt)   ise  
Helikobakter-aktive IL-10- B  hücre  örneklerinde  anlamlı  düzeyde daha fazla fosforile 
olduğu   gözlemlenmiştir.   NF-κB   sinyal   proteini   olan   p65’in   fosforilasyonunun   ise  
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örnekler   arasında   belirgin   bir   artış   veya   azalış   göstermediği   tespit   edilmiştir.   Bu  
durum ERK-1/2 aktivasyonunun Helikobakter-aktive   B   hücrelerinden   IL-10 
üretiminde   daha   etkin   rol   oynuyor   olabildiğini   düşündürmüştür. Bunun   yanı   sıra,  
spesifik  inhibitörler  kullanılarak  bloklanmış  sinyal  iletim  yolaklarının  IL-10  salınımı  
üzerindeki   etkisinin   araştırılması   sonucunda   yalnızca   ERK-1/2 inhibisyonunun B 
hücrelerinden IL-10  salınımında  anlamlı  bir  azalışa  yol  açtığı  görülmüştür.  Bu  bulgu  
da Helikobakter-aktive   B   hücrelerinden   IL-10   üretiminde   MAPK   sinyal   yolağı  
modülü  olan  ERK’in   etkin   rolü  olduğu  hipotezini  güçlendirmektedir.  Bu   çalışma  B  
hücrelerinden   TLR2-aracılıklı   IL-10   üretiminde   etkili   hücre   içi   sinyal   yolaklarını  
aydınlatması   ve  MAPK   sinyal   iletim   yolağının  ERK-1/2 modülünün  Helikobakter-
aktive  B  hücrelerinden  IL-10  üretimindeki  rolünü  göstermesi  açısından  önemlidir. 
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1.  INTRODUCTION 
 
1.1 Helicobacter felis (H. felis) 
Helicobacter felis is a small, gram negative, helical shaped, microaerophilic 
bacterium that colonizes in the stomach of cats and mice. Lee and his colleagues 
first isolated H. felis from stomach of cats in 1988 [1]. H. felis is closely related to 
Helicobacter pylori. Helicobacter pylori is a gastric pathogen that has higher 
immunogenicity for humans. Helicobacter pylori infection can result in chronic 
gastritis. The step-by-step clinical manifestations of chronic Helicobacter 
infection leading to gastric adenocarcinoma are depicted in Figure 1.1. Perpetual 
exposure to pathogen leads to gastric atrophy. Gastric mucus layer is distorted and 
gastric pH goes up due to loss of gastric chief and parietal cells, which are key 
players in maintaining gastric low pH [2]. Distortions in the protective gastric 
mucus layer enable microbial components and carcinogens to work their way into 
gastric epithelial cells in order to exert their effects on DNA and induce a number 
of changes in the cell that may lead to gastric adenocarcinoma [3]. Chronic gastric 
inflammation leads to transformation of epithelial layer of gastric tissue into 
intestinal-like epithelium, a process which is termed intestinal metaplasia. 
Perpetual exposure to the bacteria and its microbial components results in 
abnormal epithelial growth, which is termed dysplasia and subsequent gastric 
adenocarcinoma [4]. Microbial components of Helicobacter pylori are various 
virulence factors. The most significant ones that are closely associated with 
disease-causing capacity of the bacterium and severity of clinical outcome are 
cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA) [5].    
 
      Figure 1.1: Helicobacter pylori infection leading to gastric adenocarcinoma 
(adapted from ref. 5). 
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Helicobacter felis does not have CagA or VacA virulence factors. Nevertheless, the 
Helicobacter felis infection and prognosis of disease in mouse models have a striking 
resemblance to Helicobacter pylori infection in humans [6, 7]. 
1.2 Mouse Models of Helicobacter Infection 
Apart from the virulence factors of the pathogen, host genetic background is 
another determinant for the clinical outcome of the disease. Immune response to 
Helicobacter infection is divergent in two different strains of mice, which are 
commonly and widely used in Helicobacter infection studies [8].  
1.2.1 C57BL/6 mice 
T helper 1 (Th1) type immune response is induced in Helicobacter-infected 
C57BL/6 mice (Fig. 1.2). T helper 1 type immune response is associated with 
secretion of pro-inflammatory cytokines that decreases the bacterial burden while 
damaging the tissue due to perpetual gastric inflammation induced by Helicobacter 
felis infection [9,10]. Persistent H.felis infection can lead to histological alterations 
in gastric tissue of C57BL/6 mice eventually leading into gastric adenocarcinoma 
in the presence of salt diet or carcinogens [11]. 
 
 
 
 
 
 
 
 
                                      
 
                                 Figure 1.2: C57BL/6 mice (adapted from ref. 12). 
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1.2.2 BALB/c mice 
T helper 2 (Th2)-type immune response is predominant in BALB/c strain mice (Fig 
1.3) in response to Helicobacter-infection. Regarding Helicobacter-infection, in 
contrast to Th1-type response, Th2-type response is more of a tolerogenic immune 
response in which the host bacterial burden levels remain high with minimal 
damage to tissue [6]. Long-term exposure of BALB/c to Helicobacter leads to 
aggregation of lymphocytes. Therefore, BALB/c is widely used as a model for 
mucosa-associated lymphoid tissue (MALT) lymphoma [8].     
 
Figure 1.3: BALB/c mice (adapted from ref. 12). 
Approximately half of the world’s population is infected with Helicobacter 
pylori. Due to well- defined causative role of H. pylori in gastric adenocarcinoma 
formation, the bacterium was classified as a class I carcinogen by World Health 
Organization (WHO) in 1994 [13]. Increasing prevalence of Helicobacter 
infection (80%) is observed in developing countries. All individuals that are 
infected with the pathogen develop chronic gastritis, however majority of 
infected individuals are asymptomatic [14, 15]. 20% of infected individuals 
suffer from severe Helicobacter-associated gastric diseases such as peptic ulcer, 
MALT lymphoma or gastric cancer [16]. Persistent infection over time, virulence 
factors of pathogen, genetic and environmental background of the host are 
important determinants for development of severe gastric complications [17].  
The complex mechanisms underlying the asymptomacity in majority of 
Helicobacter-infected individuals have been ill-defined [18].  
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1.3 Interleukin-10 (IL-10) 
 
Interleukin-10 is an anti-inflammatory immune mediator. IL-10 was first described 
by Mosmann and colleagues as a cytokine which T helper 2 (Th2) cells produce and 
which inhibits production of Th1 cell-derived interferon-γ  (IFN-γ)  and  interleukin-2 
(IL-2)  [19].  Initially  named  as  “cytokine  synthesis  inhibiting  factor  (CSIF)”  due  to  its  
ability to suppress cytokine synthesis, this  immune  mediator  was  later  known  as  “IL-
10”  in  cytokine  nomenclature.  Today,  it  is  known  that  various  immune  cells  such  as  
CD4+ T cells, CD8+ T cells, B cells, monocytes, macrophages and dendritic cells are 
capable of producing IL-10 [20]. IL-10, owing to its pleiotropic effects, has 
significant implications on immune regulation. IL-10 represses immune response 
against pathogens and attenuates damage to host, thereby prevents autoimmunity 
[21]. 
1.3.1 IL-10 gene and protein 
The gene responsible for IL-10 expression is localized to chromosome 1 in both 
human and mouse [22]. hIL-10 is comprised of 4 exons whereas mIL-10 is 
comprised of 5 exons over a span of 5.1 kb pairs. IL-10 protein is a homodimer that 
is composed of two monomers encoded by il-10 gene. Each monomer is a protein 
comprised of 178 amino acids [23]. Cleavage of 18 amino acid-long signal peptide 
reveals the mature 160 amino acid-long mature segment. Human and murine IL-10 
proteins are found to be 75% alike regarding their amino acid sequences. Various 
viral homologs of IL-10 exist: the Epstein Barr virus (BCRF1) [24], the Herpes type 
2 virus [25], the Orf virus [26], the Cytomegalovirus [27]. Regarding amino acid 
sequence, Epstein Barr virus (BCRF1) and hIL-10 is 83% alike [28]. Due to this 
striking resemblance, acquisition of this gene was associated with the ability of virus 
to repress host antiviral immune response. [29].    
1.4  IL-10 Producing Regulatory B Cells 
B cells are significant for the humoral immune response due to their capacity to 
produce and secrete antibodies targeted against pathogens upon activation. Like 
macrophages and dendritic cells (DCs), B cells are antigen presenting cells which 
present soluble antigens to CD4+ T cells [30]. B cells are also able to produce and 
secrete various cytokines which mediate the immune response. Effector B cells can 
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be categorized into subsets depending on the type of cytokine that they produce. This 
categorization originates from the classification of cytokines produced and secreted 
by T helper (Th) cells. Th1-type cytokines such as IFN-γ   are   pro-inflammatory, 
whereas Th2-type cytokines such as IL-4, IL-5 and IL-13 are anti-inflammatory and 
associated with a tolerant response [31, 32] (Fig. 1.4). 
 
Figure 1.4: Th1 and Th2 type immune responses (adapted from ref. 33). 
Therefore   effector   B   cells   can   be   categorized   as   “Be1”   and   “Be2”,   due   to   their  
secretion of Th1-type cytokines and Th2-type cytokines, respectively. Be1 cells 
present their antigen to Th1 cells whereas Be2 cells present their antigen to Th2 cells. 
Being antigen presenting cells (APCs), effector B cells can also present the antigen 
recognized by their B cell receptor (BCR) to naive CD4+ T cells and induce them to 
take part in the immune response. The immune mediators secreted by effector B cells 
ensure sustenance of the immune response either Th1- or Th2-type, depending on the 
cytokine profile [31, 33] (Fig. 1.4).  
Reminiscent of regulatory T (Treg) cells, recently a new subset of B cells with 
regulatory function has been defined. These B cells are characterized by their 
production and secretion of anti-inflammatory cytokine interleukin-10 (IL-10). IL-10 
hampers antigen-presenting capacity of APCs, represses immune response of effector 
T cells and induces Treg formation and proliferation [33].  
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Experimental autoimmune encephalomyelitis (EAE) mouse model revealed the 
function of B cells producing IL-10 in vivo for the first time. Exacerbation of the 
disease in B-cell deficient mice was shown to be due to lack of IL-10 production by 
B cells. Excessive Th1-derived pro-inflammatory immune response persisted when 
there was no IL-10 production and secretion by B cells.  Mice could not recover from 
EAE due to excessive inflammation [34, 35]. IL-10 producing B cells have been 
shown to play an important role in restraining of excessive Th1-type immune 
response in a number of other autoimmune diseases including lupus, collagen-
induced arthritis (CIA), and colitis. [36-38]. These IL-10 producing B cells were 
called regulatory B (Breg) cells by Bhan and colleagues in 2002 due to their immune 
regulatory function [36]. 
Recent findings revealed that murine splenic B cells produce and secrete IL-10 upon 
Helicobacter-infection in vitro as well as in vivo. Helicobacter felis was found to be 
recognized by Toll-like receptor 2 (TLR2) of B cells and subsequent activation of  
myeloid differentiation primary response gene 88 (MyD88) is required for induction 
of IL-10 since TLR2 or MyD88 knock-out mice (TLR2-/- or MyD88-/-) had 
significantly less IL-10 secretion when compared to wild type (WT) mice. Gastric 
pathology developed upon Helicobacter infection was similar to WT in TLR4-/- and 
TLR9-/- mice. Moreover, both TLR2-/- and MyD88-/- mice developed accelerated 
gastric histopathology compared to WT mice. IL-10 producing regulatory B cells 
restrain excessive Th1-type pro-inflammatory immune response and gastric 
immunopathology of C57BL/6 mice via suppression of CD4+ effector T cells [18]. 
The interaction between regulatory B cells and T cells were also denoted as required 
for the function of regulatory B cells. Bregs were shown to be able to convert CD4+ 
T cells into IL-10-producing T regulatory 1 (Tr-1) cell through direct interaction. Tr-
1 cells and Bregs work in harmony in order to restore the immune balance in 
Helicobacter-infection by ameliorating excessive gastric immunopathology while 
preventing bacterial clearance in the gastric mucosa [18]. This study was significant 
for demonstrating a B cell subset with regulatory function in a bacteria-associated 
disease model for the first time. 
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1.5 Sensors of Immune System: Toll-like Receptors (TLRs) and TLR Ligands 
Several immune cells have been known to produce and secrete IL-10 through Toll-
like receptor (TLR) stimulation [75]. Toll-like receptors are sensors of the immune 
system. They recognize molecular patterns termed pathogen-associated molecular 
patterns (PAMPs) of pathogens. That is the reason why they are called pattern 
recognition receptors (PRRs) [39]. Toll protein was found to bear developmental 
significance for Drosophila when it was first identified. The importance of Toll in 
immunity as an anti-fungal protein was later delineated [40]. TLRs in mammals are 
homologous family of Toll receptors as the name suggests [41]. TLRs are found to 
be structurally reminiscent of IL-1 receptors (IL-1R) especially in their cytoplasmic 
domains which are termed as Toll-IL-1R (TIR) domains [39]. 
Humans have been shown to possess TLR1-10 whereas 12 murine TLR members 
have been identified, TLR1-9, TLR11, TLR12 and TLR13. Mice do not have a 
functional TLR10 [42]. TLRs may recognize intracellular as well as extracellular 
pathogen-related microbial patterns. Some of TLRs span the plasma membrane 
whereas some of them are localized to endosomal membrane (Fig. 1.5). Toll-like 
receptors mostly function as dimers (homodimers or heterodimers) and different 
TLRs respond to different stimuli. Known ligands of TLRs are listed in Table 1.1.  
Table 1.1: Physiological and synthetic agonists of TLRs (adapted from 43). 
TLR Physiological ligands Synthetic ligands 
 
TLR1-2 
Triacylated lipopeptides (bacteria and 
mycobacteria) 
Pam3CSK4 
 
TLR2 
Peptidoglycan (gram positive bacteria), 
multiple lipopeptides, multiple 
lipoproteins (bacteria) 
 
TLR2-6 Diacylated lipopeptides (Mycoplasma), 
zymosan (Saccharomyces cerevisiae) 
Pam2CSK4 
TLR3 dsRNA (viruses) Poly I:C 
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Table 1.1 (cont’d.): Physiological and synthetic agonists of TLRs (adapted from 
43). 
Due to their ability to recognize pathogens, TLRs are key players of innate 
immunity. However, recognition of PAMPs through TLRs can also lead to cytokine 
production and secretion from antigen presenting cells and activation of naive T and 
B cells which brings about induction of acquired immune system (either cell-
mediated or humoral immune response). Therefore, it would not be wrong to claim 
that TLRs form an essential bridge between innate and adaptive immunity [45].     
The signal received through recognition of microbial patterns is relayed through 
either MyD88-dependent or MyD88-independent pathways. All of TLRs relay their 
signal through MyD88-dependent pathway except for TLR3. TLR4 is unique in such 
a way that it can utilize both MyD88-dependent and MyD88-independent pathways 
for signal transduction. Translocation of TLR4 from plasma membrane to endosomal 
membrane brings about switching of the signal transduction from MyD88-dependent 
to MyD88-independent. [46] (Fig. 1.5). 
As an adaptor protein containing TIR domain, MyD88 enables interaction between 
IL-1R and IL-1R-associated protein (IRAK). MyD88-adaptor-like protein (MAL) 
can also act as an adaptor protein alongside MyD88 for relaying received signal. 
Ligand binding to TLR stimulates activation of IRAK through phosphorylation and 
interaction of IRAK with tumor necrosis factor (TNF) receptor-activated factors 
(TRAFs) [46, 47] (Fig. 1.5).  
 
 
 
TLR4 
LPS (gram-negative bacteria), several 
heat shock proteins (HSP60, HSP70), 
heparan sulfate fragments, 
proteoglycans, fibrinogen  
 
TLR5 Flagellin (flaggellated bacteria)  
TLR7-8 ssRNA (RNA viruses) Resquimod (R848) 
TLR9 CpG DNA (bacteria) CpG ODNs 
TLR11 Profilin-like proteins  
TLR13 23S rRNA (bacteria) [44]  
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In MyD88-independent signal transduction, ligand binding to endosomal TLR3 (and 
TLR4) leads to activation of TIR-domain-containing adaptor protein inducing 
interferon-β  (TRIF)  and  TRIF-related adaptor molecule (TRAM). TRIF and TRAM 
activation brings about the activation of TRAFs. This step is where the two signaling 
pathways are converged. Downstream signaling steps are common for two distinct 
pathways [46, 48] (Fig. 1.5).    
Activation of TRAFs results in activation of either p38 or JUN N-terminal kinase 
(JNK) of mitogen-activated protein kinase (MAPK) pathway or inhibitor of nuclear 
factor-κB   kinase   (IKK)   of   NF-κB   pathway.   Downstream transcription factors of 
these distinct pathways are cyclic AMP-responsive element-binding protein (CREB), 
activator protein-1 (AP-1), NF-κB   or   interferon-regulatory factors (IRFs). CREB, 
AP-1 and NF-κB  are  mainly   responsible   for   transcription  of   genes   coding   for  pro-
inflammatory cytokines such as IL-1β,   IL-6 and TNF-α  whereas   endosomal   TLR-
induced IRFs are responsible for transcription of type I interferons interferon-α  (IFN-
α)  and  interferon-β  (IFN-β)  as  an  initial  immune  response  to  pathogens  [46-48] (Fig. 
1.5).  
 
          Figure 1.5: TLRs and TLR signaling pathways (adapted from ref. 46). 
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1.6 Intracellular Signaling Pathways That Are Important for Induction of IL-
10 Production From Immune Cells 
 
1.6.1 MAPK/ERK signaling pathway 
 
The role of MAPK/ERK signaling pathway on induction of TLR-mediated IL-10 
production from various immune cells such as macrophages, dendritic cells (DCs) 
and T helper cell subsets has been recently identified [75]. The mitogen-activated 
protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway 
that relays a signal received by cell surface receptors through a cascade of cellular 
proteins in order to induce proper cellular response to stimuli in the form of 
transcription of related genes coding for related response proteins. The activation of 
each element in the cascade is achieved through phosphorylation by its predecessor 
[49]. Activation of cell surface receptors such as guanosine nucleotide-binding 
protein (G-protein)-coupled receptor, receptor tyrosine kinases (RTKs), B cell 
receptors (BCRs) or T cell receptors (TCRs) is the first step in an intracellular 
signaling cascade which involves phosphorylation, therefore activation of several 
kinases including MAP kinase kinase kinases (MAP3K), MAP kinase kinases 
(MAP2K) and MAP kinases (MAPK) [50-54]. Phosphorylation and activation of 
relevant MAPK molecule induces a transcription factor for transcription of a 
response gene. Ras-Raf-MEK-ERK pathway is an example for MAPK signaling 
pathway. Ligands of the receptors induce activation of G-protein which acts as a 
molecular  switch.  When  they  are  bound  to  GTP,  they  are  “on”  whereas  being  bound  
to  GDP  renders  them  “off”.  Ras is an important G-protein that is upstream of many 
intracellular signaling routes. Upon activation Ras activates its effector Raf kinase, 
which activates mitogen/extracellular signal-regulated kinase (MEK) that in turn 
activates ERK. That is why this pathway was originally called as Ras-Raf-MEK-
ERK pathway. Cancer is a likely outcome of a malfunction in signal transduction 
which renders a kinase   in   perpetual   “on”   or   “off”   state.   Six different MAPK 
signaling modules have been identified: ERK-1/2, JNK-1/2/3, p38 MAPKs  (α/β/γ/δ),  
ERK-5, ERK-3/4 and ERK-7/8. Each MAPK gets activated by a different signaling 
cascade [50]. Most researched MAPKs are ERK-1/2, JNK-1/2/3, p38 MAPKs. 
Signals elicited through p38 MAPK and ERK are relayed to relevant transcription 
factors directly or indirectly through activation of MAPK-activated protein kinases 
(MAPKAPKs) that activate specific transcription factors [51]. MAPKAPKs activated 
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through ERK-1/2 modules are ribosomal S6 kinase 1 (RSK1), RSK-2, RSK-3, RSK-
4 and MAPK-interacting kinase 2 (MNK2). p38 MAPK module activates 
MAPKAPK2, MAPKAPK3. Mitogen- and stress-activated kinase 1 (MSK-1), MSK-
2 and MNK-1 are downstream effectors of both p38 MAPK and ERK-1/2. MAPK 
modules are inactivated by dual-specificity phosphatases (DUSPs) by 
dephosphorylation via negative feedback loops [51, 52] (Fig. 1.7). 
Chemical inhibitor of p38 MAPK widely used for research purposes is SB203580. 
SB203580 blocks p38 MAPK signaling by inhibiting activation of downstream 
MAPKAPK2. It does not affect the activation of p38 MAPK module. Specific 
inhibitor of MEK-1/2 widely used for research purposes is U0126. U0126 inhibits 
phosphorylation, therefore activation of both MEK-1 and MEK-2 and downstream 
effectors [51] (Fig. 1.6).  
Cellular responses elicited through activation of MAPK/ERK pathway depend upon 
stimuli. ERKs mainly respond to growth factors and mitogens and their response 
mainly involve cell proliferation and differentiation. JNKs are also known as stress-
activated protein kinases (SAPKs) and as the name suggests JNKs along with p38 
MAPKs are responders of DNA damage, oxidative stress, heat shock and cytokines. 
The typical responses elicited through these signaling nodes are cell differentiation, 
apoptosis and cytokine production [50-54]. Figure 1.7 demonstrates the stimulants, 
modules, kinases and effectors of MAPK signaling pathway. 
 
Figure 1.6: MAPK signaling pathways leading to downstream effector MAPKAPKs 
(modified from ref. 51). 
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          Figure 1.7: Overview of MAPK signaling pathway (adapted from ref. 52). 
1.6.2 PI3K pathway 
The contribution of PI3K signaling pathway on IL-10 production upon TLR-
stimulation has been revealed with studies performed in macrophages [75]. 
Phosphoinositide 3‑kinase (PI3K) pathway is pivotal for cell proliferation, survival 
and growth in response to cytokines, growth factors and hormones. PI3K is activated 
when ligands bind to their receptors such as a receptor tyrosine kinase (RTK). 
Activated PI3K turns membrane-bound Phosphatidylinositol 4,5-bisphosphate (PIP2) 
into Phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Akt (a.k.a. Protein kinase B 
(PKB)) gets translocated to plasma membrane in order to interact with PIP3. The 
phosphorylation, therefore activation of Akt is achieved in two-steps. 3-
phosphoinositide dependent protein kinase-1 (PDK1) phosphorylates Akt at Thr308 
whereas mammalian target of rapamycin (mTOR)-rictor complex (mTORC2) 
phosphorylates Akt at Ser473 (Fig. 1.8). Phosphatase and tensin homolog (PTEN) is 
the designated negative-regulator of PI3K/Akt signaling pathway as it reverses 
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conversion of PIP2 to PIP3. Overactivity of Akt signaling can lead to malignancies 
such as cancers due to uncontrolled cell proliferation [54-56]. 
Dual phosphorylation of Akt results in phosphorylation of many downstream effector 
molecules. mTOR is one of the most important effectors of Akt as it leads to cell 
cycle progression and cell growth. Glycogen synthase kinase-3 (GSK-3) is also 
another effector. GSK-3 differs from other kinases as its activity is inhibited through 
phosphorylation. Phosphorylation at Ser21 and Ser9 renders GSK-3α   and  GSK-3β  
inactive, respectively. Phosphorylated GSK-3 has pleiotropic effects on many 
cellular processes including cell cycle progression (Cyclin D1), glycogen 
metabolism. Akt inhibits apoptosis by inhibitory phosphorylation of many pro-
apoptotic effectors such as Bad, Bim and Forkhead transcription factors (FoxO1, 
FoxO3a) [54-56]. Figure 1.8 depicts the molecules, kinases and effectors of PI3K 
signaling pathway. 
Selective inhibitors of PI3K or Akt block PI3K signaling pathway. One of the widely 
used inhibitors of PI3K is LY294002. LY294002, the first synthetic PI3K inhibitor 
abrogates activity of PI3K and its downstream effector molecules [55].  
 
Figure 1.8: Overview of PI3K signaling pathway (adapted from ref. 56). 
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1.6.3 NF-κB  pathway 
The involvement of NF-κB   signal   transduction   pathway   in   TLR-stimulated IL-10 
production from immune cells such as macrophages has been designated [75]. 
Nuclear factor-κB   (NF-κB) pathway elements play a central role in innate and 
adaptive immune responses and inflammation. NF-κB/Rel  proteins  are  p50/105  (NF-
κB1),   p52/100   (NF-κB2),   p65   (RelA),   c-Rel and RelB. Functional dimers of these 
proteins act as transcription factors. There are two distinct pathways for NF-κB  
signaling: canonical and non-canonical pathways [57]. 
1.6.3.1 Canonical (classical) pathway  
Classical pathway is induced with ligands such as LPS, growth factors, pro-
inflammatory cytokines and antigens recognized by their cognate receptors. 
Received  signals  activate  IKK  complex  which  is  composed  of  IKKβ,  IKKα,  and  NF-
κB  essential  modulator  (NEMO)  by  phosphorylation.  Activated  IKK  complex  brings  
about phosphorylation of nuclear factor of kappa light polypeptide gene enhancer in 
B-cells   (IκB)   proteins   which   are   bound   to   NF-κB1/RelA   proteins   and   when  
unphosphorylated  inhibit  their  activation.  IκB  proteins  are  ubiquitinated  and  targeted  
for   degradation   upon   phosphorylation.   Degradation   of   IκB   renders   NF-κB1/RelA  
proteins functionally active. Phosphorylated and active p50/p65 heterodimer 
translocates into the nucleus and acts as transcription factor or co-transcription factor 
of AP-1, signal transducer and activator of transcription (STAT) for expression of 
several response genes [57,58] (Fig. 1.9).  
1.6.3.2 Non-canonical (alternative) pathway  
NF- κB2  p100/RelB  proteins  reside  in  cytoplasm in inactive form when there are no 
stimuli. Ligands such as lymphotoxin-β   (LTβ),   CD40L   or   B-cell activating factor 
(BAFF) exert their effect by inducing a signaling cascade involving sequential 
phosphorylation of NF-κB  inducing  kinase  (NIK),  IKKα  complex  and  NF-κB2  p100  
subunit. Processing of precursor p100 into mature p52 occurs upon phosphorylation 
and ubiquitination of p100. Functionally active p52/RelB heterodimer goes into the 
nucleus and induce expression of response genes [57-59] (Fig.1.9). 
There are many chemical inhibitors of NF-κB  signaling.  Being  one  of   them,  PDTC  
(Pyrrolidinedithiocarbamate ammonium) exerts its effect by inhibiting degradation of 
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IκBα.   IκBα   is   normally   ubiquitinated   and   targeted   for   degradation   by   proteosomal  
proteolytic pathway in order to enable formation and translocation of p50/p65 
heterodimer into nucleus [60].   
 
Figure 1.9: NF-κB canonical and non-canonical signal transduction pathways                                                                                       
(adapted from ref. 58). 
1.7 IL-10 Receptor and IL-10/IL-10R Signaling 
Biological activity of IL-10 is mediated by its specific transmembrane receptor 
complex (IL-10R). IL-10R is comprised of IL-10R1 (the ligand-binding chain) and 
IL-10R2 (the accessory chain), both of which are members of the class II cytokine 
receptor family (CRF2) [23]. Binding between IL-10 and IL-10R complex is a two-
step process. IL-10 first binds to IL-10R1 and this interaction between IL-10 and IL-
10R1 induces a conformational change in cytokine structure, revealing an epitope to 
enable interaction between IL-10 and IL-10R2. Therefore, the interaction of IL-
10/IL-10R1 complex enables binding of IL-1R2 since IL-10R2 is unable to interact 
with IL-10 alone [61] (Fig. 1.10).        
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Figure 1.10: Interaction scheme between IL-10 and IL-10 receptor complex (adapted                                                                                                                                                                    
from ref. 23). 
IL-10R1 is predominantly found on immune cells. Unlike IL-10R1, various cells 
express IL-10R2 [62]. IL-10 exerts its effects through Janus kinase (JAK) / Signal 
transducer and activator of transcription (STAT) pathway. Jak1 and Tyk2 are 
activated following binding of IL-10 to its receptor complex. These two kinases 
belong to Janus Kinase family and interaction partners of Jak1 and Tyk2 are IL-10R1 
and IL-10R2, respectively. This activation leads to phosphorylation of IL-10R1 on 
tyrosine residues Tyr 446 and Tyr 496. This is followed by binding of STAT3, a 
transcription factor, to phosphorylated tyrosine domains and phosphorylation, 
therefore activation of STAT3 by receptor-associated Janus kinases [63]. STAT1 and 
STAT5 were also found to be activated in response to IL-10 in murine pre-B cell line 
transfected with mIL-10 receptor coding gene [64]. Activated STAT transcription 
factors are translocated into nucleus in the form of phosphorylated homo- or hetero-
dimers and start transcription of IL-10-induced genes by binding to the response 
elements of STAT molecules [63]. The suppressor of cytokine signaling 3 (SOCS3) 
is one of the IL-10-induced genes. As the name suggests, SOCS3 inhibits expression 
of pro-inflammatory cytokines such as Tumor Necrosis Factor-α  (TNF-α),  IL-1, IL-
6. Expression of SOCS3 in response to IL-10 in monocytes and macrophages is 
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found to be closely related to inhibition of expression of endotoxin-inducible (LPS- 
or IFN-induced) genes [29, 65]. 
1.8 Effects of IL-10 on Immune Cells 
As previously implicated, IL-10 has various pleiotropic effects on immune cells. 
Antigen presenting cells, especially monocytes and macrophages are characterized 
by their hallmark features like phagocytosis, antigen presentation and cytokine 
release to elicit an immune response. One of the impacts of IL-10 is limiting the 
secretion of macrophage-derived pro-inflammatory cytokines such as TNF-α,  IL-1β,  
IL-6 and IL-8, thereby hampering innate immune response-related cytokine release 
[66]. Another aspect of IL-10 influence on monocytes/macrophages is repression of 
antigen presentation. This inhibition is accomplished by decreased expression of 
major histocompatibility complex class II (MHC-II) molecules, co-stimulation 
molecules such as CD86 and adhesion molecules such as CD54, each of which do 
take an active role in binding and antigen presentation between antigen presenting 
cell and its interaction partner (e.g. CD4+ T cell) [23]. IL-10 is also capable of 
limiting Th1- and Th17-mediated immune responses by reducing the secretion of IL-
12 and IL-23 from APCs, respectively. IL-12 is the cytokine responsible for Th1-
type T cell conversion from naive CD4+ T cells whereas IL-23 is known to be pivotal 
for Th17 immune response [67]. Phagocytosis efficiency of APCs is enhanced by IL-
10 via increasing expression of cell surface receptors that enable internalization of 
pathogens. It has been shown that treatment of monocytes with IL-10 induces 
expression of CD16, CD32, CD64 Fc receptors that are crucial for uptake of 
opsonized (being marked for phagocytosis) material and CD14 which acts as a co-
receptor for the internalization of microorganisms that are not opsonized [68]. IL-10 
also prevents killing of internalized pathogens while circumventing the complement 
system attack on phagocytes [69].  
The effects of IL-10 on T cells, apart from its indirect effects elicited through APCs, 
are mainly impeded cell proliferation and repression of Th1- (e.g. IL-2, IFN-γ)   or  
Th2-type cytokine (e.g. IL-4, IL-5) secretion from CD4+ T helper cells [70]. IL-10 
produced by TLR2-activated B cells has also been implicated with their potency to 
convert CD4+ T cells into IL-10 producing regulatory T cells (Treg), which are also 
termed as T regulatory-1 (Tr-1) cells, in vitro in a contact-dependent manner [18].  
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IL-10 acts on B cells as a growth factor which enables and enhances expansion, 
differentiation and Ig class switching of B cells. IL-10 is also capable of increasing 
the expression of MHC-II on cell surface [23].   
Since NF-κB  signaling  is  central  for  expression  of  many  pro-inflammatory cytokines, 
NF-κB  has  been  a  potential  target for IL-10 to exert its limiting effects on cytokine or 
chemokine secretion [71]. Indeed, in monocytes and macrophages, IL-10 was shown 
to inhibit canonical pathway of NF-κB  signaling,  that  is  translocation  of  functionally  
active p50/p65 heterodimer into nucleus [72]. Inhibition of NF-κB  signaling  by  IL-
10 may be via bilateral molecular mechanisms as depicted in Figure 1.11. IL-10 may 
hamper the translocation of functionally active p50/p65 heterodimer via IKK 
inhibition or inhibit binding of translocated heterodimer to relevant DNA region 
[73]. An IL-10 favored p50/p50 homodimer translocation instead of p50/p65 
heterodimer was also suggested. These p50/p50 homodimers are known for their 
inhibitory effect on transcription unlike their p50/p65 heterodimer counterparts [74].     
 
Figure 1.11: Molecular mechanisms used by IL-10 to inhibit NF-κB   activity 
(adapted from ref. 74). 
1.9 Regulation of IL-10 Production From Immune Cells 
Macrophages, dendritic cells (DCs) and neutrophils have been shown to secrete IL-
10 both in vitro and in vivo upon stimulation of relevant PRRs [75]. IL-10 production 
of antigen presenting cells is found to be stimulated by ligands for TLR2 as seen in 
the case of Mycobacterium tuberculosis-activated DCs [76, 77]. IL-10 production 
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pathways independent from TLR2 signaling have also been defined like the 
designated role of nucleotide-binding oligomerization domain 2 (NOD2) in 
macrophages activated by pneumoccocal cell wall [78]. LPS and CpG, ligands for 
TLR4 and TLR9, respectively, are also found to be alternative signals that elicit IL-
10 production in macrophages, myeloid DCs and B cells [79, 80] In myeloid DCs, 
induction of IL-10 production can also be maintained through cell surface proteins 
DC-specific ICAM3-grabbing non-integrin (DC-SIGN) inducing RAF1 or PRR 
dectin-1 inducing spleen tyrosine kinase (SYK). Subsequent activation of ERK by 
SYK is required for IL-10 production [81, 82].    
Upon stimulation through TLR, activation of ERK1/2 was found to be central for IL-
10 production since lack of ERK of chemical suppression of phosphorylation 
capacity of ERK resulted in less IL-10 production [76, 83-84]. A correlation between 
expression and activation levels of ERK and IL-10 production levels has been 
revealed. Indeed, macrophages, that produce high amounts of IL-10, had high levels 
of ERK activation when compared to myeloid DCs which do produce moderate 
amounts IL-10 due to moderately activated ERK. Plasmacytoid DCs on the other 
hand, had no IL-10 production owing to low levels of activated ERK [84] (Fig. 1.12). 
 
Figure 1.12: ERK expression-dependent IL-10 production from different immune 
cell types (adapted from ref. 75). 
In macrophages and myeloid DCs TLR-mediated signals are relayed either in 
MyD88-dependent of MyD88-independent manner. MyD88-dependent pathway 
utilizes activation of MAPKs (p38 or ERK), PI3K or NF-κB  whereas   in  MyD88-
independent way TRIF-TRAF3 interactions are pivotal for IL-10 production. ERK 
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gets activated by tumor progression locus 2 (TPL2), a MAP3K. The interaction 
between p105 subunit of NF-κB  and  TPL2   is   important   for  ERK  activation.  TLR-
mediated signal enables TPL2 to detach from p105/TPL2 complex, which then can 
induce activation of ERK. p105/TPL2 complex protects of TPL2 from degradation, 
thereby ensures activation of ERK. Macrophages lacking either p105 or TPL2 were 
shown to produce less IL-10 upon TLR-stimulation when compared to wild-type 
controls [84-86]. CREB, as the common downstream effector of TLR-mediated 
signal relayed through different cascades is activated by phosphorylation at Ser133. 
PI3K activation leads to phosphorylation and activation of Akt. Akt, then 
phosphorylates GSK-3β.   As   previously   mentioned,   GSK-3β   is   active   when  
unphosphorylated. Active GSK-3β  is  known  to  inhibit  binding  of  CREB  to  DNA  by  
phosphorylating CREB at Ser129 residue rendering it inactive [87]. Functional GSK-
3β   also   inhibits  DNA  binding   activity   of  AP1.   Phosphorylation   by  Akt   inactivates  
GSK-3β,  enabling  binding  of  CREB  and AP1 to DNA for expression of IL-10 [88] 
(Fig. 1.13). 
IL-10 production from APCs (macrophages and DCs) is under both negative and 
positive regulation. IFN-γ   acts   as   negative   regulator   of   both   MAPK- and PI3K-
mediated IL-10 production [88]. IFN-γ  exerts  its  effect on GSK-3β  by  inhibiting  its  
phosphorylation therefore blocking its inactivation. Active GSK-3β   inhibits   IL-10 
expression. IL-10 induces a negative feedback loop on its own production through 
activation of dual-specificity phosphatase 1 (DUSP1). DUSP1 dephosphorylates, 
therefore inactivates p38 MAPK signaling [89]. Production of IL-10 is positively 
regulated through increased TPL2 expression [90]. Also, IL-10 leads to an increase 
of its own production via STAT3 activation [91]. Figure 1.13 demonstrates 
regulation of IL-10 production in antigen presenting cells of the innate immune 
system. 
p65 subunit of NF-κB   was   found   to   interact   with   IL-10 coding DNA region in 
murine macrophages stimulated by LPS for IL-10 production [92]. On the other 
hand, p50 subunit of NF-κB  was  found  to  interact  with  promoter  region  of  IL-10 in 
HuT78 cells, a human T cell lymphoma cell line [75]. p50/p50 homodimers, which 
were thought to have an inhibitory effect on NF-κB-induced gene expression, were 
found to induce IL-10 production in LPS-stimulated primary murine macrophages 
[93].  
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Figure 1.13: Regulation of IL-10 production in APCs of innate immune system 
(adapted from ref. 75).  
CD4+ Th1 cells are known for their signature pro-inflammatory immune response 
(IFN-γ  secretion), therefore they do not normally secrete IL-10. However, it has been 
shown that high antigen exposure and IL-12 together can elicit IL-10 secretion from 
Th1 cells [94]. Th1 cells utilize ERK and STAT4 pathways for IL-10 expression 
[95]. Th2 cells produce IL-10 through IL-4 mediated ERK and STAT6 signaling. T 
cell receptor-triggered IL-10 production from Th17 subset depends on ERK and 
STAT3 signaling [75, 95-96]. ERK signaling for IL-10 production seems to be 
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shared by many immune cells. On the other hand, unlike macrophages and DCs, T 
helper subsets do not utilize p38 MAPK or GSK-3β  signaling  for   IL-10 expression 
since abrogation of p38 or GSK-3β  signaling  with  appropriate  inhibitor  did  not  result  
in alteration of IL-10 production detected by intracellular flow staining [95]. Figure 
1.14 depicts IL-10 production pathways utilized by T helper cell subsets.        
 
Figure 1.14: IL-10 production pathways in T helper cell subsets (adapted from ref. 
75). 
IL-10 has been shown to be produced by other immune cell subsets such as 
regulatory T cells (Treg), CD8+ T cells, B cells. B cells are known to produce IL-10 
via TLR4 or TLR9 stimulation [37, 96-99]. Recently B cell derived IL-10 production 
via TLR2 stimulation by Helicobacter felis was identified in mouse models [18]. 
Human B cells are shown to produce IL-10 upon stimulation with TLR7/8 and TLR9 
ligands [100]. However, the intrinsic signaling pathways of IL-10 production in B 
cells have not been researched extensively. Recently, the role of p38 MAPK 
signaling pathway has been identified for murine B cell-derived IL-10 expression 
and secretion upon TLR4 and TLR9-stimulation [80]. In the case of human B cells, 
ERK and STAT3 pathways have been designated as central pathways for TLR7/8 or 
TL9-mediated IL-10 production [100]. Nevertheless, TLR2-mediated signal 
transduction pathways leading to IL-10 production and secretion still remain ill-
defined.   
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1.10 Aim of the Study 
B cells are known to produce IL-10 in TLR-dependent manner [75]. TLR2-, TLR4-, 
TLR7/8 and TLR9-stimulation elicit IL-10 production from B cells [75, 80, 100]. 
TLR4- and TLR9-stimulated murine B cells were found to utilize p38 MAPK 
module of MAPK pathway rather than ERK-1/2 module [80] whereas ERK-1/2 and 
STAT3 activation were required for induction of IL-10 production from TLR7/8-
stimulated human primary B cells [100].  
Helicobacter felis sonicate is recognized by TLR2 on B cells and elicits IL-10 
production and secretion [18]. Even though TLR2-dependent IL-10 production from 
other APCs (macrophages and DCs) has been extensively researched [75], the 
intrinsic pathway(s) regulating IL-10 production from B cells upon TLR2-
stimulation has/have not been clearly identified. The aim of this study is to identify 
and elucidate the signaling nodes that take part in TLR2-mediated IL-10 production 
and secretion in vitro. For this purpose, splenic murine B cells are stimulated with 
Helicobacter felis sonicate to determine activation of certain signaling kinases that 
take part in induction of IL-10 production. Based upon previous studies on IL-10 
production from immune cells such as macrophages, dendritic cells, T helper cell 
subsets [75], MAPK/ERK, PI3K and NF-κB  signaling  pathways  were  chosen  as the 
main focus of investigation. In order to further elucidate the role of putative signaling 
node(s) on IL-10 production from Helicobacter-activated B cells, these signaling 
pathways were blocked with specific chemical inhibitors and any change in IL-10 
secretions were investigated.  
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2. MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Bacteria 
Helicobacter felis (H. felis) strain   was   kindly   provided   by   Prof.   Dr.   Anne  Müller  
from University of Zurich. They were grown in Columbia Agar plates supplemented 
with 1000X antibiotic cocktail. Ingredients of Columbia Agar (BD, U.S.A.) plate and 
1000X antibiotic cocktail were given in Table 1 and Table 2, respectively. Solutions 
and chemicals that are used in maintenance of Helicobacter felis are given in Tables 
1.1 and 2.1. 
Table 2.1: Components of Columbia Agar Plates. 
Component Amount 
Columbia Agar 42,5 g 
Horse Blood 50 ml 
β-cyclodexin 10 ml 
1000X Antibiotic Cocktail 1 ml 
Table 2.2: Components of 1000X Antibiotic Cocktail. 
Content Amount 
Trimethoprim 100 mg 
Amphotericin B 160 mg 
DMSO 20 ml 
 
2.1.1.1 Antibiotics 
 
Antibiotics that are used in Helicobacter felis culture are listed in Table 2.3. 
Table 2.3: Antibiotics used in Helicobacter felis culture. 
Content Supplier Company 
Trimethoprim HiMedia 
Amphotericin B HiMedia 
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2.1.1.2 Liquid culture  
Ingredients of liquid culture of Helicobacter felis are shown in Table 2.4 with a 
representative volume of 50 ml. The volume of ingredients may change depending 
on the required volume of components for proper growth of bacteria.   
Table 2.4: Components of Helicobacter felis liquid culture. 
Content Amount 
Brucella Broth 50 ml 
FBS [10% (v/v)] 5 ml 
Vancomysin (1000X) 5  µl 
2.1.1.3 Freezing of Helicobacter felis 
The medium suitable for freezing Helicobacter felis for stock purposes is depicted in 
Table  2.5  with  its  ingredients.  Upon  preparation  the  medium  can  be  stored  at  4°C. 
Table 2.5: Freezing medium for Helicobacter felis. 
Component Amount  
Brucella Broth 25 ml 
Glycerol  25 ml 
2.1.2 Primary cell line 
CD19+ splenic naive B cells were obtained from C57BL/6 mice via magnetic 
separation (Macs Miltenyi, Germany). Primary B cells were cultured in Roswell Park 
Memorial Institute (RPMI) medium supplemented with 10% FBS, 1% 
Penicillin/Streptomycin. Purified CD19+ B cells were stimulated with either 
Helicobacter felis sonicate, lipopolysaccharide (LPS) or CpG. CpG was kindly 
provided  by  Prof.  Dr.  İhsan  Gürsel  from  Bilkent  University,  Ankara. 
2.1.3 Buffers and solutions  
Buffers and solutions that were used in different steps of this study are listed in 
Tables 2.6-2.9. 
2.1.3.1 Cell culture 
Culture media and solutions that were used in cell culture studies can be seen in 
Table 2.6 and buffers that are used in cell culture studies are listed in Table 2.7. 
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Table 2.6: Solutions and media used in cell culture studies. 
Solution Supplier Company 
Roswell Park Memorial Institute (RPMI) 
Medium 
Lonza 
Fetal Bovine Serum (FBS) (10%) Lonza 
Penicillin/Streptomycin (1%) Gibco 
Trypan Blue Lonza 
DMSO Fisher-Scientific 
Table 2.7: Buffers used in cell culture studies. 
Buffer Content and Amount 
PBS 1X 9,55 g in 1L ddH2O 
MACS Buffer 0.5% BSA 
2 mM EDTA in PBS 1X 
FACS Buffer  2% FBS in PBS 1X 
2.1.3.2 Protein extraction 
Components and amounts of Radioimmunoprecipitationassay (RIPA) Buffer that 
was used in extraction of total proteins from cell pellets are listed in Table 2.8.  
Table 2.8: RIPA Buffer used in protein extraction. 
Content Amount 
50 mM Tris-HCl (pH:7.4) 5 ml of 1M 
1% NP-40 1 ml 
0.5% Na-deoxycholate 2.5 g 
0.1 % SDS 0.5 g 
150 mM NaCl 3 ml of 5M 
2 mM EDTA 0.4 ml of 0.5 M 
50 mM NaF 1.05 g 
ddH2O up to 100 ml 
2.1.3.3 Western Blotting  
Buffers and solutions that were used in Western Blotting studies are listed in Table 
2.9. 
Table 2.9: Buffers and solutions used in Western Blotting. 
Buffer/Solution Content and Amount 
Protein Ladder (7-175 kDa) New England Biolabs 
Blocking solution 5% nonfat dry milk or 5% BSA in 
TBS/T 
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Table 2.9 (cont’d.): Buffers and solutions used in Western Blotting. 
2.1.3.4 IL-10 ELISA 
Solutions that were used in IL-10 ELISA studies are given in Table 2.10.  
Table 2.10: Solutions used in IL-10 ELISA experiments. 
Solution Content  
PBS/T 1X 0.05% Tween-20 in PBS 1X 
Stop Solution  2N H2SO4 in ddH2O 
10% SDS-polyacrylamide 
separating gel 
4 ml ddH2O 
3.3 ml 30% Acrylamide Mix 
2.5 ml 1.5 M Tris (pH 8.8) 
0.1 ml 10% SDS 
0.1 ml 10% APS 
5  µl  TEMED 
5% SDS-polyacrylamide 
stacking gel 
3.4 ml ddH2O 
0.83 ml 30% Acrylamide Mix 
0.63 ml 1.0 M Tris (pH 6.8) 
0.05 ml 10% SDS 
0.05 ml 10% APS 
6  µl  TEMED 
Ponceau S staining solution 
0.1 g Ponceau S 
5 ml Glacial Acetic Acid 
up to 100 ml ddH2O 
 
Running Buffer 10X (pH: 8.3) 
15 g Tris base (25 mM) 
71.2 g Glycine (192 mM) 
50 ml 10% SDS (0.1%) 
up to 1 L ddH2O 
 
Transfer Buffer 10X 
58.2 g Tris base 
29.3 g Glycine 
37.5 ml 10% SDS 
up to 1 L ddH2O 
 
Transfer Buffer 1X 
100 ml Transfer Buffer 10X 
200 ml Methanol 
700 ml ddH2O 
Laemmli Buffer 5X 
1.5 g SDS 
3.75 ml 1 M Tris-HCl (pH 6.8) 
0.015 g Bromophenol Blue 
1.16 g DTT 
7.5 ml Glycerol 
up to 15 ml ddH2O 
Tris Buffered Saline (TBS) 10X    
     (pH: 7.4) 
24.23 g Tris base 
80.06 g NaCl 
up to 1 L ddH2O 
TBS/T 1X 100 ml TBS 10X in 1L ddH2O 1 ml Tween-20 
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2.1.4 Equipment 
Laboratory equipments which were used in this study are shown in Table 2.11 with 
their suppliers. 
Table 2.11: Laboratory equipment used in this study. 
Equipment Supplier Company 
Laminar Air Flow Cabinets FASTER BH-EN 2003 
Pipettes 10  µl,  20  µl,  100  µl,  200  µl,  1000  µl  
Socorex and  10  µl,  100  µl,  1000  µl  
Biohit 
Electronic Pipette CappAid 
Centrifuges 
Beckman  Coulter  Allegra  ™  25  R  
Centrifuge 
Scanspeed 1730 R 
Labogene Scanspeed mini 
Incubator with CO2 BINDER 
Vortex Mixer Uzusio VTX-3000L,LMS 
Quick spin LMS  
Magnetic stirrer WiseStir MSH-20D, Wisd Laboratory 
Equipment 
pH Meter Mettler Toledo MP220 
Light Microscope Olympus CH30 
Hemacytometer Isolab 
Ice Machine Scotsman AF10 
Freezers 
Altus ( + 4 0C) 
Siemens ( -20 0C) 
Haier (- 80 0C) 
Power Supply BIO-RAD 
SDS-PAGE Gel Electrophoresis System BIO-RAD 
Shakers Heidolp Duomax 1030 
Kodak Medical X-Ray Processors Kodak 
Flow Cytometer BD Accuri C6 
Densitometer GS-800 
Thermo shaker Biometra TS1 ThermoShaker 
Sonicator Bandelin Sonopuls 
Nitrogen Tank Air Liquid 
Microplate Spectrophotometer BIO-RAD Benchmark Plus 
Tissue flask Sarstedt 
Serologic pipettes Dispenser 
Centrifuge tubes Interlab 
Eppendorf tubes (0.6 ml, 1.5 ml, 2 ml) Interlab 
Nitrocellulose  membrane  (0.2  µm  pore  
size) 
Santa Cruz 
Scale Precisa 
Examination Gloves Beybi 
Cell  strainer  (70  µm) BD 
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Table 2.11 (cont’d.): Laboratory equipment used in this study. 
Tissue culture flasks (25 cm2, 75 cm2) Sarstedt 
Anaerobic Jar Anaerocult 
Whatman Filter Paper (3 mm) Whatman 
Erlens Isolab 
Falcons (15 ml, 50 ml) Isolab 
Slides  Interlab 
Coverslips Interlab 
Cotton Swap Interlab 
96-well F plate (for ELISA studies) Nunc 
 
2.1.5 Commercial kits 
Commercial kits that were used in this study are listed with their supplier companies 
in the table below. 
                            Table 2.12: Commercial kits used in this study. 
Kit Supplier Company 
Mouse B Cell Isolation Kit MACS, Miltenyi Biotec 
Mouse Regulatory B cell Isolation Kit MACS, Miltenyi Biotec 
BCA™  Protein  Assay  Reagent  Assay Thermo Scientific 
20  X  LumiGLO®Reagent  and  20  X  
Peroxide 
Cell Signaling 
Mouse IL-10 Deluxe Max ELISA Biolegend 
PathScan®  Signaling  Nodes  Multi-
Target Sandwich ELISA Kit  
Cell Signaling 
2.1.6 General chemicals 
General chemicals used in this study are listed with their supplier companies in Table 
2.13. 
Table 2.13: General chemicals used in this study. 
Chemical Supplier Company 
Acetic Acid (glacial) Merck 
EDTA Applichem 
Ethanol (absolute) Merck 
NaCl Merck 
Glycerol Merck 
Phosphate-Buffered Saline (PBS) 10X Lonza 
Ammonium persulfate (APS) Fisher-Scientific 
Tween-20 Fisher-Scientific 
Bovine Serum Albumin (BSA) Santa Cruz 
DMSO Fisher Scientific 
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Table 2.13 (cont’d): General chemicals used in this study. 
2.1.7 Antibodies 
Antibodies that were used in this study are given in Table 2.14. 
Table 2.14: Antibodies used in this study. 
Antibody/Inhibitor Clone  Supplier 
Company 
Application 
Rabbit anti-CREB mAb 48H2 Cell Signaling WB 
Rabbit anti-Phospho-CREB 
(Ser133) mAb 
87G3 Cell Signaling WB 
Mouse anti-GSK-3β  mAb 3D10 Cell Signaling WB 
Rabbit anti-Phospho-GSK-3β  
(Ser9) mAb 
D85E12 Cell Signaling WB 
Rabbit anti-p44/42 MAPK 
(Erk1/2) mAb 
137F5 Cell Signaling WB 
Rabbit anti-Phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) mAb 
D13.14.4E Cell Signaling WB 
Rabbit anti-Akt (Pan) mAb C67E7 Cell Signaling WB 
Sodium Deodecyl Sulfate (SDS) Fisher Scientific 
TEMED Sigma-Aldrich 
Acrylamide- Bis-acrylamide (40%) Fisher Scientific 
Bromophenol Blue Fisher Scientific 
Nonfat dry milk powder Organic Valley 
PMSF Applichem 
Nonidet P-40 (NP-40) Applichem  
HALT Protease Inhibitor (100X) Thermo Scientific 
PhosSTOP Phosphatase Inhibitor (10X)  Roche 
DTT Applichem 
β-Mercaptoethanol Sigma-Aldrich 
Ponceau S Fisher Scientific 
Methanol Sigma-Aldrich 
Isopropanol Sigma-Aldrich 
HCl Sigma-Aldrich 
NaOH Sigma-Aldrich 
Glycine Fisher Scientific 
Tris base (Trizma base) Sigma-Aldrich 
NaF Alfa Aesar 
Columbia Agar BD 
Brucella Broth BD 
CampyGen 2.5L Oxoid 
Lipopolysaccharide (LPS) Sigma-Aldrich 
Fixation Buffer 1X Biolegend 
Permeabilization Buffer 10X Biolegend 
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Table 2.14 (cont’d.) : Antibodies used in this study. 
Rabbit anti-Phospho-Akt 
(Thr308) mAb 
C31E5E Cell Signaling WB 
Rabbit anti-p38 MAPK 
mAb 
D13E1 Cell Signaling WB 
Rabbit anti-Phospho-p38 
MAPK (Thr180/Tyr182) 
mAb 
D3F9 Cell Signaling WB 
Mouse anti-Vinculin mAb hVIN-1 Sigma WB 
Anti-rabbit IgG, HRP-
linked Antibody 
- Cell Signaling WB 
Anti-mouse IgG, HRP-
linked Antibody 
- Cell Signaling WB 
Rat anti-mouse CD19-FITC 6D5 Biolegend FACS 
 
 
Rat anti-mouse IL-10-PE 
Mouse 
Regulatory 
B Cell 
Isolation kit 
component  
 
 
MACS Miltenyi 
 
 
FACS 
7-AAD Staining Solution - BD FACS 
 
2.1.8 Inhibitors 
Inhibitors which were used in this study are listed with their suppliers and working 
concentrations in Table 2.15. 
Table 2.15 : Inhibitors used in this study. 
Inhibitor Working concentration Supplier Company 
U0126 (MEK-1/2 
inhibitor) 
15  µM Cell Signaling 
SB203580 (p38 MAPK 
inhibitor) 
10  µM Cell Signaling 
LY294002 (PI3K 
inhibitor) 
15  µM Cell Signaling 
PDTC (NF-κB inhibitor) 30  µM Tocris Bioscience 
2.1.8.1 MEK-1/2 inhibitor (U0126) 
5 mg of lyophilized MEK-1/2 inhibitor (U0126) was reconstituted in 1.31 ml of 
DMSO prior to use in order to get 10 mM stock solution. Stock solution was 
aliquoted and stored at -20°C.  Working  concentration  of  U0126  was  15  µM. 
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2.1.8.2 p38 MAPK inhibitor (SB203580) 
5 mg of lyophilized p38 MAPK inhibitor (SB203580) was reconstituted in 1.32 ml of 
DMSO prior to use in order to get 10 mM stock solution. Stock solution was 
aliquoted and stored at -20°C.  Working  concentration  of  SB203580  was  10  µM. 
2.1.8.3 PI3K inhibitor (LY294002) 
1.5 mg of lyophilized PI3K inhibitor (LY294002) was reconstituted in 488   µL   of  
DMSO prior to use in order to get 10 mM stock solution. Stock solution was 
aliquoted and stored at -20°C.  Working  concentration  of  LY294002  was  15  µM. 
2.1.8.4 NF-κB  inhibitor  (PDTC) 
50 mg of lyophilized NF-κB   inhibitor   (PDTC)   was   reconstituted   in 3.04 ml of 
DMSO prior to use in order to get 100 mM stock solution. Stock solution was 
aliquoted and stored at -20°C.  Working  concentration  of  PDTC  was  30  µM. 
2.2 Methods 
2.2.1 Maintenance of Helicobacter felis 
Helicobacter felis was seeded on a Columbia blood agar containing appropriate 
antibiotics  and   incubated  at  37°C  under  microaerophilic  conditions   in  an  anaerobic  
jar for 3-4 days. Microaerophilic conditions in anaerobic jar were maintained by 
utilization of CampyGen packs. For preparation of Columbia agars, 42,5 g Columbia 
agar was dissolved in 1000 ml water. Liquid was autoclaved. The bottle was put in 
50 0C  water  for  1  hour.  50  ml  horseblood  was  added  to  agar.  10  ml  β-cyclodexin and 
1 ml of 1000 X antibiotic cocktail (see Table 2.2) was added for H. felis growth. 
After 3-4 days, the grown bacteria was checked under light microscope for their 
viability and mobility and transferred into liquid Brucella Broth containing 10.000 X 
Vancomysin (final concentration: 1X) with necessary dilutions for optimal growth. 
For preparation of Brucella Broth medium, 28 g of brucella broth powder was 
resuspended in 1L of sterile distilled water (ddH2O). Following resuspension, the 
liquid  medium  was  autoclaved  at  121°C  for  15  min  for  sterilization.   
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2.2.2 Sonication of H. felis strain 
Sonication procedure was initiated with 120-200 ml liquid culture of Helicobacter 
strains. Before sonication mobility and viability of Helicobacter felis (10  µl) were 
checked under light microscope. 120- 200 ml liquid culture of Helicobacter felis was 
aliqouted into 15 ml falcons. Falcons were centrifuged at 1500 rpm for 10 minutes. 
Supernatant was discarded. 10 ml PBS was used to wash bacteria. 15 ml falcons 
were centrifuged at 1500 rpm for 10 minutes. Supernatant was discarded. 3.5 ml PBS 
was added on pellet and mixed. Sonication was performed as 30 sec pulse on; 50 sec 
pulse off for 6.30 minutes at 50 watt on ice to prevent excessive heat formation. (MS 
72 probe of the sonicator was used.) Sonicate was aliquoted to 1.5 ml eppendorfs at 
500 µl   for   each.   They   were   centrifuged   at   15,000   rpm   for   20   minutes   at   4°C.  
Supernatants were transferred into new eppendorf tubes and labeled. Sonicate 
concentration was measured with BCA assay. 
2.2.3 Protein bicinchoninic acid (BCA) assay 
For determination of Helicobacter felis sonicates after sonication and determination 
of  protein  samples  after  cell  lysis,  Thermo  Scientific’s  Pierce  Protein  BCA  Assay  Kit  
was used. Bovine Serum Albumin (BSA) Standard Set was chosen for microassay. 
According to the total number of samples and Bovine Serum Albumin (BSA) 
standards,  working   reagent   (200  µl  per   sample)  was  prepared from Solution B and 
Solution A as 1:50 ratio, respectively and was warmed to ambient temperature. 200 
µl  of  working  reagent  was  distributed  into  each  assayed well of a 96-well F-bottom 
plate, and all the samples and standards were used in duplicates in order to obtain 
more  accurate  results.  10  μl of diluted BSA standards in duplicates were added into 
corresponding working reagent-containing wells with the concentrations of 0,025; 
0,125; 0,25; 0,5; 1; 1,5; 2 mg/mL, respectively. Dilution scheme for BSA standards 
are   given   in   Table   2.16.   10   μl of protein samples (diluted of undiluted) with 
unknown concentrations were added to corresponding working reagent-containing 
wells,  and  plate  was  covered  and  incubated  at  37°C  for  at  least  30  min.  After  30  min-
long incubation, the plate was cooled to room temperature and absorbances were 
measured at 562 nm on microplate reader.  
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Table 2.16: Dilution scheme for BCA Assay standards. 
Vial Volume of diluents 
ddH2O (µl) 
Volume & source of BSA 
(µL) 
Final BSA 
Concentration 
(µg/ml) 
A 0 300 of stock 2,000 
B 125 375 of stock 1,500 
C 325 325 of stock 1,000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0 = Blank 
2.2.4 Treatment of purified B cells  
Purified B cells were treated with H. felis sonicates with a final concentration of 10 
µg/ml.  They  were   incubated  with  or  without  H. felis sonicate for 24 h. After 24 h-
long incubation, IL-10 producing regulatory B cell subset was magnetically labelled 
and separated from H. felis sonicate-treated cells by using Mouse Regulatory B Cell 
Isolation Kit (MACS Miltenyi, Germany) The procedures for both B cell and 
regulatory B cell isolations are explained in detail in upcoming sections. LPS and 
CpG were also used as stimulation agents for CD19+ B cells for 48h-long 
stimulation.  LPS  was  used  at  10  µg/ml  final  concentration  whereas  CpG  was  used  at  
5  µg/ml  final  concentration  in  cell  culture  studies.   
2.2.5 Mouse B cell isolation  
Splenic B cells were isolated using Mouse B Cell Isolation Kit (MACS Miltenyi). 
The procedure is explained in detail in sections 2.2.5.1-2.2.5.4.  
2.2.5.1 Cell preparation 
Spleen obtained from a sacrificed C57BL/6 mouse was  put   in   the  center  of  70  µm  
filter mesh carefully by the help of a tip. Spleen was meshed on the filter mesh with 
the plunger of a syringe single cell suspension of the spleen was prepared in a 50 ml 
falcon tube. Incomplete RPMI medium was used to soak filter and rinse cells from 
filter to the tube. Procedure was repeated for all obtained spleens. Tube was filled 
with incomplete medium. Cell suspension was centrifuged at 1480 rpm (200g) for 10 
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minutes. Supernatant was discarded. Cell pellet was dissolved in 1 ml MACS buffer 
per spleen. Cell number was determined. Cells were counted by diluting with MACS 
buffer (~1:200). Cell viability was checked with trypan blue. 
2.2.5.2 Pre-enrichment of B cells 
After cell number and viability was determined, cell suspension was centrifuged at 
1780 rpm for  8  minutes.  Cell  pellet  was  resuspended  in  40  µl  of  MACS  buffer  per  
107 cells.   Then   10   µl   of   B   Cell   Biotin-Antibody Cocktail (containing antibodies 
targeted against CD4, CD43 and Ter-119) was added per 107 cells. Tube was mixed 
well and incubated at refrigerator   for  15  min.  30  µl  of  MACS  buffer   and  20  µl  of  
Anti-Biotin MicroBeads were added per 107 total cells. Tube was mixed well and 
incubated in refrigerator for another 15 min. Cells were washed with 1-2 ml of 
MACS Buffer per 107 cells. Cell pellet was resuspended  in  500  µl  of  MACS  buffer  
per 108 cells. 
2.2.5.3 Magnetic separation: depletion of non-B cells 
LS column (if total cell number is less than 2x108 MS column is more suitable for 
purification) was placed in suitable MACS separator (Midi) on magnetic field. 
Column was activated by rinsing with 3 ml of cold MACS buffer. Cell suspension 
was applied onto the column. Column was washed by 3x3 ml of MACS buffer and 
time was always given for the reservoir to be emptied between washing steps. 
Flowthrough was unlabeled B cells. Column was removed from magnetic field and 
put in a 15 ml falcon tube. The magnetically labeled non-B cells were flushed out 
with 5 ml of MACS buffer by firmly pushing the plunger of the column. Cell number 
was determined by diluting 1:10 with MACS buffer and cell viability was checked 
with trypan blue under light microscope. Flow cytometer analysis for CD19 surface 
marker was performed in order to determine purity of B cells. 
2.2.5.4 Flow staining for CD19 surface marker 
Purity of freshly purified splenic B cells was determined using flow cytometer. 5x105 
B cells and depleted non-B   cells   were   stained   with   0.2   µl   FITC   conjugated   anti-
CD19  antibody  in  50  µl  FACS  Buffer   in   the  dark  on  ice  for  at   least  45  minutes.  A  
fraction of B and non-B cells were left as unstained controls. Then, cells were 
washed once with 1 ml FACS Buffer by centrifugation at 3000 rpm for 8 minutes. 
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Supernatant  was  discarded  and  pellet  was  resuspended  in  150  µl  of  FACS  Buffer  and  
samples (both unstained and stained) were analyzed on flow cytometer.    
2.2.6 IL-10 producing regulatory B cell isolation 
IL-10 producing subset of B cells was magnetically separated by Mouse Regulatory 
B Cell Isolation Kit (MACS Miltenyi). The detailed procedure for isolation of IL-10 
producing regulatory B cells is explained in sections 2.2.6.1-2.2.6.6.  
2.2.6.1 In vitro stimulation 
Isolated CD19+ B cells were centrifuged at 1780 rpm for 8 minutes. Cell pellet was 
resuspended in proper amount of medium (2.5x106 cells/ml). Cells were incubated in 
96-well U bottom plates with stimulation agent (Helicobacter felis sonicate) for 24 h 
long incubation (Final concentration: 10 µg/ml).   Cells   which   were   not   stimulated  
with sonicate were kept as control B cells. PMA (50 ng/ml) and ionomycin (500 
ng/ml) were added for the last 5 hours of incubation in order to induce IL-10 
secretion from Helicobacter-stimulated B cells. 
2.2.6.2 Labeling cells with Regulatory B Cell Catch Reagent 
Cells were harvested by collecting into a falcon tube by pipetting up and down. The 
wells also washed with MACS Buffer in order to ensure harvesting of all B cells. 
Cell number was determined by diluting 1:10 with MACS Buffer. For cell viability 
check, trypan blue staining was performed. Cells were washed by adding MACS 
buffer and centrifuged at 1780 rpm for 8 minutes. Supernatant was discarded 
carefully.  Cell  pellet  was  resuspended  in  90  µl  of  cold  medium  per  107 total cells. 10 
µl  of  Regulatory  B  Cell  Catch  Reagent  was  added  per  107 total cells. Regulatory B 
Cell Catch Reagent is a specific molecule which has two binding domains one of 
which recognizes CD45 on B lymphocytes and the other recognizing IL-10. Tube 
was mixed well and incubated on ice for 5 min.  
2.2.6.3 IL-10 secretion period 
10 ml warm medium was added per 107 cells. Cells were incubated in closed tube for 
45 min at 37 0C. Tube was turned upside down every 5 minutes to resuspend settled 
cells. In this period, the aim was basically to catch IL-10 secreted from Helicobacter-
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stimulated B cells on cell surface following binding of catch reagent to CD45 surface 
marker on B cells. 
2.2.6.4 Labeling cells with Regulatory B Cell Detection Antibody (PE) 
The tube was filled with cold MACS buffer. The tube was incubated on ice for 5 
min. in order to prevent non-specific antibody binding. Cells were centrifuged at 
1780 rpm for 8 minutes. Supernatant was discarded carefully. Cell pellet was 
resuspended   in   90   µl   of  MACS   buffer   per   107 total cells. A fraction of unlabeled 
cells were separated as unstained   control.   10   µl   of   Regulatory   B   Cell   Detection  
Antibody (PE) was added per 107 total cells. Tube was mixed well and incubated for 
15 min on ice. In this step, IL-10 which was secreted from Helicobacter-stimulated B 
cells and caught on cell surface via catch reagent was labeled by a PE-conjugated IL-
10 detection antibody. 10 ml of cold MACS buffer was added for washing and the 
tube was centrifuged at 1780 rpm for 8 minutes. Supernatant was discarded carefully. 
2.2.6.5 Magnetic labeling with Anti-PE MicroBeads 
Cell  pellet  was  resuspended  in  80  µl  of  cold  buffer  per  107 total  cells.  20  µl  of  Anti-
PE MicroBeads were added per 107 total cells. Tube was mixed well and incubated 
for 15 min in the refrigerator. This step enabled magnetic labeling of IL-10 
producing Helicobacter-activated B cells by anti-PE Microbeads which is bound to 
PE-conjugated IL-10 detection antibody. Cells were washed by adding 10 ml of cold 
MACS buffer per 107 total cells. Tube was centrifuged at 1780 rpm for 8 minutes. 
Supernatant was discarded  carefully.  Cell  pellet  was  resuspended   in  500  µl  of  cold  
MACS buffer (up to 5x107 cells, the working dilution was 108 cells/ml for higher cell 
numbers). 
2.2.6.6 Magnetic separation using MS Column 
MS column (up to 2x108 total cells) was placed on mini MACS Separator in the 
magnetic   field.  Column  was  activated  by   rinsing  with   the  500  µl  of  MACS  buffer.  
Cell suspension was applied onto the column. Unlabeled cells (IL-10 negative B cell 
fraction) were collected as flow-through and column was washed 3 times  with  500  µl  
MACS buffer. Column was removed from separator and put on a falcon tube. 1 ml of 
MACS buffer was pipetted onto the column and magnetically labeled cells (IL-10 
positive B cell fraction) were flushed out by plunger. Cell numbers were determined 
 39 
 
by diluting 1:10 with MACS buffer and cell viability was checked with trypan blue 
under light microscope. Flow cytometer analysis was performed for IL-10-PE in 
order to check the purity of IL-10 positive and IL-10 negative fractions. A fraction of 
B+H.f. cells before addition of PE-coupled IL-10 detection antibody was separated as 
unstained control. The steps of procedures including splenic murine CD19+ B cell 
isolation and separation of B cells according to their IL-10 production capacity 
following stimulation with H. felis sonicate for 24 hours are displayed in Figure 2.1. 
 
Figure 2.1: Purification of murine splenic B cells and subsequent separation of B 
cells according to their IL-10-production capacities. CD19+ B cells 
were purified from murine splenic cells (splenocytes) by negative 
selection (Macs Miltenyi). All splenocytes except for CD19+ cells were 
magnetically labeled by an antibody cocktail and CD19+ B cells were 
acquired as flow through in a magnetic field. Purified B cells were 
cultured (2,5x106 cells/ml) in the presence of H.felis sonicate  (10µg/ml)  
for 24 h. PMA (50 ng/ml) and ionomycin (500 ng/ml) were added into 
the culture during the last 5 h in order to induce IL-10 secretion. 
Following 24 h-long incubation, cells were harvested and labeled with a 
compound called Regulatory B Cell Catch Reagent (Macs Miltenyi) that 
was designed to capture secreted IL-10 at IL-10 secretion period on the 
cell surface. Then, cells were magnetically labeled with an PE-
conjugated IL-10 detection antibody. Upon application of a magnetic 
field, IL-10 producing B cells (IL-10+ B) were kept in the column 
(Macs Miltenyi) whereas IL-10 negative B cells (IL-10-B) were 
acquired as flow-through. IL-10+ B cells were obtained by subsequent 
flushing-out of cells from the column. 
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2.2.7 Intracellular flow staining for IL-10 
In order to determine intracellular IL-10 production levels via flow cytometry, 
purified CD19+ B cells were either treated with H. felis sonicate for 24 hours or left 
untreated. IL-10  secretion  was  blocked  by  2  µM  monensin  5  hours  before  harvesting  
of the cells. A fraction of ctrl B, B+H.f. cells were left as unstained controls. After 
harvesting of the cells by centrifugation at 3000 rpm for 8 minutes, cells were fixed 
with  100  µl  of  Fixation  Buffer  (Biolegend)  for  20  minutes  on  ice.  Following  fixation,  
cells  were  washed  with  500  µl  of  FACS  Buffer  once  by  centrifugation  at  3000  rpm  
for  8  minutes.  Supernatant  was  discarded  and  pellets  were  resuspended  in  175  µl  of  
1X Permeabilization Buffer (diluted from 10X with ddH2O). Cells were centrifuged 
at   3000   rpm   for   8   minutes.   Pellets   were   reconstituted   in   175   µl   of   1X  
Permeabilization Buffer once more. Cells were centrifuged at 3000 rpm for 8 
minutes. Pellets were resuspended in  50  µl  of  permeabilization  buffer  containing  0.2  
µl   of   PE-coupled anti-mouse IL-10 detection antibody (MACS Miltenyi) and 
samples were stained in the dark on ice for 1 hour. Following 1 hour long incubation 
on   ice,   cells   were   washed   with   175   µl   permeabilization buffer by centrifugation. 
Pellets  were  washed   once   in   500  µl   of   FACS  Buffer   by   centrifugation   and   pellets  
were  resuspended  in  150  µl  of  FACS  Buffer  and  analyzed  on  flow  cytometer. 
2.2.8 Protein extraction 
For whole cell lysis, after snap-freezing cell pellets in liquid nitrogen, pellets were 
resuspended in appropriate amounts of RIPA Buffer containing freshly added 0.1 M 
PMSF (final concentration: 0.5 mM), 100X HALT Protease Inhibitor Cocktail (final 
concentration: 1X) and 10X Roche Phosphatase Inhibitor Cocktail (final 
concentration: 1X). After complete resuspension, samples were incubated on ice for 
at least 30 minutes. Then, they were centrifuged at 14,000 rpm for 10 min. 
Supernatants were aliquoted as total protein samples. Protein concentrations were 
determined by Protein BCA Assay and protein samples were stored at -80°C. 
2.2.9 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis is a technique 
widely used for separation of proteins. The proteins are separated in SDS gel 
according to their molecular weight. In this study, 5% stacking gel and 10% 
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separating gels were used. Prepared gel mixtures were poured in between short plates 
and spacer plates (1 mm) and polymerized. Isopropanol was used to overlay 
separating gel in order to facilitate polymerization and ensure flattening the surface 
of the gel. For phosphorylation studies, since many of the phosphorylated and total 
forms of proteins gave bands at approximately at the same region, two separate gels 
were cast, one for total protein detection and the other for phospho-protein detection. 
After gels were polymerized, samples, that were mixed with 5X Laemmli Buffer and 
boiled  at  100°C  for  5  minutes,  were  loaded  in  corresponding  wells  of  SDS  gel.  The  
amounts of loaded protein sample were ensured to be equal for each well. The gels 
were placed into the electrophoresis tank and protein samples were run in running 
buffer 1X. The running voltage was kept at 90V during the samples were running in 
the stacking gel (for approximately 30 minutes). After the samples were stacked, the 
voltage was increased up to 120V or 150V and samples were run for approximately 2 
more hours ensuring the target protein would not run off the gel.  
2.2.10 Western blotting 
Western blotting is used to detect specific proteins from total protein repertoir of a 
cell. Following SDS-PAGE, SDS gels were removed from the tank and stripped off 
from short and spacer plates. Transfer of proteins from gel to the nitrocellulose 
membrane   was   performed   by   wet   transfer   (at   160V   for   1h   at   4°C).   Following  
transfer, the transferred proteins were visualized by Ponceau S staining. Ponceau S 
staining was performed by incubating the newly-transferred nitrocellulose membrane 
in Ponceau S solution for at least 5 minutes with gentle shaking. Reversibly bound 
Ponceau S bands (reddish) were made visible following rinsing of the membrane in 
distilled  water.  After  destaining  in  distilled  water,  the  blots  were  blocked  at  4°C  for  
1h in blocking solution (5% nonfat dry milk in TBS/T) to prevent non-specific 
binding.  
Blocked membranes were then incubated overnight with relevant primary antibodies 
appropriately   diluted   in   TBS/T   containing   5%   BSA   at   4°C   with   gentle   shaking.  
Following day, membranes were washed with TBS/T buffer 3 times for a total of 30 
minutes with gentle shaking. Appropriately diluted secondary antibody was prepared 
in blocking solution, and membranes were incubated with relative secondary 
antibody for 1-2  hour  at  4°C.  After  washing  of  the  membrane  with  TBS/T  for  3  x  10  
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miutes,  20X  LumiGLO®  Reagent  was  used   as   1X  diluted   in  distilled   sterile  water  
(ddH2O) for the detection of  proteins  according   to  manufacturer’s   instructions.  The  
membrane was exposed to X-ray film for a certain amount of time and then 
following enough exposure, the X-ray film was developed in Kodak Medical X-ray 
Processor  according  to  manufacturer’s  instruction.  
The antibodies that were used in western blotting studies are listed in Table 2.17 
along with their working dilutions and supplier companies. 
Table 2.17: Antibodies used in Western Blotting. 
Antibody Clone  Dilution Supplier 
Company 
Rabbit anti-CREB mAb 48H2 1:1000 Cell Signaling 
Rabbit anti-Phospho-CREB 
(Ser133) mAb 
87G3 1:1000 Cell Signaling 
Mouse anti-GSK-3β  mAb 3D10 1:1000 Cell Signaling 
Rabbit anti-Phospho-GSK-
3β  (Ser9)  mAb 
D85E12 1:1000 Cell Signaling 
 
Rabbit anti-p44/42 MAPK 
(Erk1/2) mAb 
137F5 1:1000 Cell Signaling 
 
Rabbit anti-Phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) mAb 
D13.14.4E 1:2000 Cell Signaling 
Rabbit anti-Akt (Pan) mAb C67E7 1:1000 Cell Signaling 
Rabbit anti-Phospho-Akt 
(Thr308) mAb 
C31E5E 1:1000 Cell Signaling 
Rabbit anti-p38 MAPK 
mAb 
D13E1 1:1000 Cell Signaling 
Rabbit anti-Phospho-p38 
MAPK (Thr180/Tyr182) 
mAb 
D3F9 1:1000 Cell Signaling 
Mouse anti-Vinculin mAb hVIN-1 1:1000 Sigma 
Anti-rabbit IgG, HRP-
linked Antibody 
2°  Ab 1:3000 Cell Signaling 
Anti-mouse IgG, HRP-
linked Antibody 
2°  Ab 1:3000 Cell Signaling 
2.2.11 Inhibitor studies 
For inhibitor studies, purified CD19+ splenic B cells (2,5x106 cells/ml) were pre-
incubated with or without following inhibitors with indicated concentrations for 
duration  of  1  h  at  37°C.  DMSO  was  also  used  at  indicated  concentrations  as  a  vehicle  
control for each inhibitor. 
- U0126 (MEK-1/2  inhibitor)  (final  concentration:  15  µM) 
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- SB203580  (p38  MAPK  inhibitor)  (final  concentration:  10  µM) 
- LY294002 (PI3K inhibitor) (final  concentration:  15  µM) 
- PDTC (NF-κB  inhibitor)  (final  concentration:  30  µM) 
Following 1 h-long incubation, B cells were either stimulated with Helicobacter felis 
sonicate   (final   conc:   10µg/ml)   or   left   unstimulated   for   24   h.   After   24   h-long 
incubation, cells pellets were harvested and stored at -80°C   for   further   protein  
isolation, and cell culture supernatants were aliqouted for further IL-10 ELISA 
experiments. 
2.2.12 IL-10 ELISA 
IL-10   protein   levels   in   supernatant   of   samples   were   determined   by   Biolegend’s  
Mouse IL-10 ELISA Deluxe Max Kit. For quantitative determination of IL-10 
protein in culture medium of B cells, Nunc 96-well plates were coated with IL-10 
capture antibody  1:200  diluted  in  coating  buffer  1X  and  plate  was  incubated  at  4°C  
overnight.  Following  day,  plate  was  washed  four  times  with  PBS/T.  Then,  100  µl  of  
Assay Diluent A 1X (diluted from 5X with PBS 1X) was added into assayed wells 
and the plate was incubated at room temperature for 1h. Recombinant IL-10 
standards  were  prepared  by  serial  dilution  according  to  manufacturer’s   instructions.  
After that, plate was again washed four times with PBS/T. Following washing steps, 
diluted recombinant IL-10 standards   and   culture   media   supernatants   (50   µl)   were  
added as biological duplicates. Plate was incubated at room temperature for 2 h. 
Following 2 h-long incubation, plate was washed four times with PBS/T. 
Biotinylated IL-10 detection antibody diluted 1:200 in Assay Diluent 1X was added 
into each assayed well and plate was incubated at room temperature for 1 h. After 
washing of assayed wells with PBS/T for three times, Avidin-HRP solution 1:1000 
diluted  in  Assay  Diluent  A  1X  was  added  into  each  assayed  well  as  50  µl and plate 
was incubated in the dark for 30 min at room temperature. After 30 min-long 
incubation,  plate  was  washed  for  five  times  with  PBS/T  and  50  µl  of  TMB  Substrate  
Solution Mixture (1:1 of TMB Substrate A and TMB Substrate B) was added into 
each assayed well. The plate was incubated for at least 30 minutes at room 
temperature. High concentration standards and samples turned into blue. After that, 
the  reaction  was  stopped  with  50  µl  stop  solution  (2N  H2SO4). Then, the absorbances 
of the samples were measured at 450 nm on a microplate reader.  
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2.2.13  PathScan®  Signaling  Nodes  Multi-Target Sandwich ELISA 
Cell   Signaling’s  Pathscan  Signaling  Nodes  Multi-Target Sandwich ELISA Kit is a 
complex kit which enables detection of many key signaling molecules such as 
phospho-Akt, phospho-p38 MAPK, phospho-MEK-1/2, phospho-STAT3, phospho-
NF-κB  p65.  Only  p-STAT3 and phospho-NF-κB  p65  detection  was  utilized  for  this  
study. The wells on strips of the microplate were pre-coated with either anti-STAT3 
antibody or anti-phospho-NF-κB  p65  antibody.  After   the  microwells   reached   room  
temperature, required strips were separated and the rest of the strips were sealed and 
incubated  at  4°C.  The  protein  samples  of  ctrl  B,  B+H.f., Helicobacter-activated IL-
10- B and IL-10+ B were diluted with sample diluent provided by the kit. They were 
assayed at protein concentration of approximately 0.15 mg/ml.   75   µl   of   diluted  
protein samples were added into appropriate wells as duplicates. The wells were 
sealed with the sealing tape. The plate was   incubated  overnight   at   4°C.  Following  
overnight incubation, the plate was washed 4 times with 1X wash buffer (diluted 
from 20X wash buffer provided with ddH2O). After each wash, the plate was tapped 
upside down on fresh towels, but the wells were not allowed to dry between wash 
steps.   After   washing   step,   50   µl   of   detection   antibody   solution   was   added   into  
corresponding wells. Matching of the color code on the cap of the detection antibody 
and color code of the 8-well strip was ensured. After that, the plate was sealed again 
and   incubated  at  37°C  for  1  hour.  Following  1-hour-long incubation, the plate was 
washed   again   for   4   times.   After   washing   steps,   50   µl   of   HRP-linked secondary 
antibody was added into corresponding wells. Matching of the color code on the cap 
of the HRP-linked secondary antibody and color code of the 8-well strip was ensured 
once  again.  The  wells  were  sealed  with  tape  and  the  plate  was  incubated  at  37°C  for  
30 minutes. Following 30-minutes- long   incubation,   50   µl   of   TMB   substrate   was  
added  into  each  well.  The  wells  were  sealed  with  tape  and  incubated  at  25°C  for  30  
minutes. After 30 minutes, the reaction was stopped by   addition   of   50   µl   of   stop  
solution provided by the kit. Color changing from blue to yellow was observed upon 
stop solution addition. After stopping of the reaction, the absorbance values of the 
samples were determined at 450 nm on a microplate reader.    
2.2.14 Flow cytometry analyses 
Flow cytometry analyses were performed using FlowJo software.  
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2.2.15 Densitometric analyses 
Densitometric analyses were performed to detect the densities of protein bands of the 
target proteins and normalize their density to that of housekeeping protein (vinculin). 
X-ray films were scanned in Bio-Rad GS-800 densitometer and densitometric 
analyses were performed using Adobe PhotoShop CS5 Software. Densitometric 
values of protein bands were determined by multiplying index and mean levels of 
each protein band and these values were normalized to their corresponding 
housekeeping controls (vinculin levels). Phosphorylation percentages of target 
proteins were determined by the ratio of densitometric values of phospho-proteins 
over total-proteins normalized to their internal control. Phosphorylation percentages 
were graphed using GraphPad Prism 5.0 software. Standard deviations of the mean 
are indicated by vertical bars in column bar graphs, n.d. denotes not determined. 
2.2.16 Statistical analyses     
All p values were calculated using GraphPad Prism 5.0 software. Significancies 
were determined by Student t test. In all analyses, a two-tailed p-value of less than 
0.05 was considered statistically significant. In column bar graphs, vertical bars 
indicate standard deviations of the mean, n.d. stands for not determined, and n.s. 
denotes not significant. 
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3. RESULTS  
 
3.1 Isolation of Splenic Naive B Cells From C57BL/6 Mice  
B cells were purified from spleen of C57BL/6 mice by negative selection. Negative 
selection involves magnetic labeling of total splenic cells (splenocytes) except for B 
cells and acquiring unlabeled B cells as flow-through upon exposure of splenocytes 
to magnetic field. Splenic B cell purity was determined by B cell-specific surface 
marker CD19 surface staining upon isolation of CD19+ B cells. Figure 3.1 shows a 
representative flow staining of purified B cells compared to unstained control. Purity 
of isolated and cultured B cells was more than 97 %.  
 
Figure 3.1: Purity of B cells isolated from spleen of C57BL/6. Representative flow 
cytometry plot of purified B cells compared to unstained control. B 
cells were magnetically isolated from spleen of C57BL/6 mice by 
negative selection. 5x104 of isolated cells were either stained with 
FITC-coupled anti-CD19 antibody (0.5  µg/µl) or left unstained (isotype 
control) in order to detect the percentage of cells expressing B cell-
specific surface marker CD19. Values in quadrants indicate percentages 
of cells. 
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3.2 Purity of IL-10- B and IL-10+ B Cells Magnetically Separated Upon 
Helicobacter felis (H. felis) Sonicate Treatment  
In order to obtain IL-10-producing B cells upon Helicobacter-sonicate treatment, B 
cells were subjected to magnetic separation (explained in detail at section 2.2.6) 
following 24h-long incubation with H.felis sonicate treatment. Since the fundamental 
logic of the separation was capturing secreted IL-10 on the surface of IL-10 secreting 
B cells with an anti-IL-10-PE antibody, determining the purity of separated fractions 
(IL-10 negative B cells and IL-10 positive B cells) depended upon PE flow readings 
(Fig. 3.2). Purity of magnetically separated Helicobacter-activated IL-10+ B cells and 
IL-10- B cells were >84% and >86%, respectively. 
 
 
 
 
 
 
 
 
Figure 3.2: Purity of IL-10– B and IL-10+   B   cells magnetically separated from 
splenic B cells following H. felis sonicate treatment.  
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Figure 3.2 (cont’d.): Purity of IL-10– B and IL-10+  B  cells magnetically separated 
from splenic B cells following H. felis sonicate treatment. IL-
10 secretion from B cells was induced by addition of PMA 
(50 ng/ml) and ionomycin (500 ng/ml) during the last 5 h of 
24 h-long incubation with H.felis sonicate at   10  µg/ml   final  
concentration. H.felis sonicate-stimulated B cells were then 
magnetically separated into IL-10– B and IL-10+   B   cell  
fractions   and   IL-10   levels   of   these   fractions   compared   to  
unstained   isotype   control   were   determined   by   flow  
cytometry.  Upper  panel  shows  representative  flow  cytometry  
plots   of   three   independent   experiments   (n=3).   Values in 
quadrants indicate percentages of cells. GraphPad Prism 5.0 
was used to graph average percentage for IL-10 positivity of 
each fraction (lower panel).  
3.3 Assessment of IL-10 Production From Helicobacter felis - treated B Cells 
In order to determine IL-10 production levels of H. felis - treated B cells compared to 
untreated control, CD19+ splenic B cells, were cultured as untreated (ctrl B) or 
treated with H. felis sonicate (B+H.f.) for 24 h. IL-10 production levels were 
determined by intracellular flow staining (Fig. 3.3).  
 
 
Figure 3.3: IL-10 production levels of untreated splenic B cells and B cells treated 
with H. felis sonicate. B cells were either treated with H.felis sonicate at 
10  µg/ml  final  concentration (B+H.f.) or left untreated (ctrl B) for 24 h. 
Monensin (2 µM)  was   added   into   culture  medium   during   last 5 h of 
incubation. Following fixation and permeabilization, cells were either 
stained with PE-coupled anti-IL-10 antibody (0.2 µg/µl) or left 
unstained (isotype control) in order to detect percentage of cells 
producing IL-10. Values in quadrants indicate percentages of cells.   
According to flow readings, 67,08% of H. felis sonicate–treated B cells were found 
to be positive for IL-10 whereas 3,8% untreated B cells were positive for IL-10 after 
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24 hour-long incubation. These results suggest that B cells produce IL-10 upon 
stimulation with Helicobacter felis sonicate. 
3.4 Assessment of IL-10 Secretion From Helicobacter felis - treated B Cells 
B cells were shown to produce IL-10 upon Helicobacter-stimulation (Fig. 3.3). In 
order to determine IL-10 secretion levels of H. felis sonicate - stimulated B cells 
compared to untreated control, CD19+ splenic B cells were cultured as untreated (ctrl 
B) or treated with H. felis sonicate (B+H.f.) for 24h. Supernatants of cultured B cells 
were then investigated for secreted amounts of IL-10 (Fig. 3.4).  
  
Figure 3.4: IL-10 secretion levels of untreated splenic B cells and B cells treated 
with H. felis sonicate. B cells were either treated with H.felis sonicate at 
10  µg/ml  final  concentration (B+H.f.) or left untreated (ctrl B) for 24 h. 
Following 24 h-long incubation, cell culture supernatants were probed 
for IL-10 by IL-10 ELISA. Data are representative of three independent 
experiments (n=3). GraphPad Prism 5.0 was used to graph mean levels 
of secreted IL-10 amount. Statistical analysis was conducted using 
Student’s  t test. 
IL-10 ELISA results indicated that B cells treated with H. felis sonicate secreted 
significantly more IL-10 (2-fold) than untreated B cells. Results of intracellular 
staining for IL-10 and IL-10 ELISA collectively demonstrated that splenic B cells 
could be induced to produce and secrete IL-10 by stimulation with Helicobacter felis 
sonicate.  
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3.5 Assessment of IL-10 Secretion Levels of Helicobacter-activated IL-10– B and 
IL-10+  B  Cells 
In order to determine IL-10 secretion levels of Helicobacter-activated IL-10– B and 
IL-10+  B  cells, magnetically separated IL-10– B cells and IL-10+    B  cells were further 
cultured with H. felis sonicate for 48h. Supernatants of cultured cells were then 
investigated for secreted amounts of IL-10 (Fig. 3.5).  
 
Figure 3.5: IL-10 secretion levels of Helicobacter-activated IL-10– B and IL-10+    B  
cells treated with H. felis sonicate for 48 h. B cells were treated with 
H.felis sonicate  at  10  µg/ml  final  concentration  for  24 h. Following 24 
h, Helicobacter-activated B cells were magnetically separated into IL-
10– B cells and IL-10+      B   cells.   IL-10– B and IL-10+   B   cells   were  
cultured   in   the   presence   of   H.felis   sonicate   (10µg/ml)   for   48   h.  
Following  48  h-long   incubation, cell culture supernatants were probed 
for IL-10 by IL-10 ELISA. Data are representative of three independent 
experiments (n=3). GraphPad Prism 5.0 was used to graph mean levels 
of secreted IL-10 amount. Statistical analysis was conducted using 
Student’s  t test. 
ELISA results indicated that secreted IL-10 was significantly more (8-fold) in IL-10+  
B cells compared to IL-10– B cells. This result was expected since magnetic 
separation of Helicobacter-activated B cells was performed depending on IL-10 
production capacity of these subsets. Secretion of IL-10 from IL-10- B cells upon 
stimulation with H.felis sonicate may be attributed to expansion of 12% IL-10 
producing B cells in  IL-10- B fraction that was observed as impurity (Fig. 3.2).   
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3.6 The Role of MAPK/ERK Pathway on IL-10 Production From Helicobacter-
stimulated B Cells 
3.6.1 The role of p38 MAPK on IL-10 production 
Phosphorylation, therefore activation of p38 MAPK was found to be required for IL-
10 production from TLR-stimulated macrophages, DCs and TLR4- or TLR9-
stimulated primary murine B cells [75, 80].  In order to determine the role of p38 
MAPK on induction of IL-10 production from Helicobacter-activated B cells, 
protein samples of ctrl B, B+H.f., Helicobacter-activated IL-10- B cells and IL-10+ B 
cells were investigated for phosphorylation of p38 MAPK by Western Blotting (Fig. 
3.6).  
 
Figure 3.6: Assessment of phosphorylation levels of p38 MAPK. 
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Figure 3.6 (cont’d.): Assessment of phosphorylation levels of p38 MAPK. Splenic B 
cells were stimulated with H. felis sonicate for 24 h (B+H.f.). 
Control B (ctrl B) cells did not receive any treatment. Upon 
addition of PMA (50ng/ml) and ionomycin (500ng/ml) during 
last 5h of 24h-long incubation, H. felis-stimulated cells were 
magnetically separated as IL-10– B and IL-10+ B cells. Cells 
were lysed and whole cell extracts were immunoblotted for p-
p38 MAPK and p38 MAPK. Vinculin was used as loading 
control. Western Blotting results (upper panel) are 
representative of three independent experiments (n=3). 
GraphPad Prism 5.0 was used to graph densitometric analysis 
results (lower panel). Statistical analysis was conducted using 
Student’s t test. 
 
Western Blotting results indicated that p38 MAPK was significantly less 
phosphorylated (~40%) in H.felis-stimulated B (B+H.f.) cells when compared to 
unstimulated B (ctrl B) cells (~50%). Comparison of p38 MAPK phosphorylation 
between Helicobacter-activated IL-10– B and IL-10+ B cells revealed that IL-10– B 
had significantly more phosphorylated p38 MAPK (~80%) than IL-10+ B cells 
(~50%). Phosphorylation percentages were found to be higher in Helicobacter-
activated IL-10– B and IL-10+ B fractions when compared to B+H.f. sample possibly 
due to the induction of these fractions with PMA and ionomycin. This result suggests 
that activation of p38 MAPK may play a more prominent role in Helicobacter-
activated IL-10- B cells rather than IL-10+ B. 
3.6.2 The role of MEK-1/2 on IL-10 production 
ERK-1/2 activation was shown to be required for induction of IL-10 production from 
macrophages, DCs and T helper subsets (Th1, Th2, Th17) [75]. MEK-1/2 is 
upstream activator of ERK-1/2 in ERK-1/2 signaling module of MAPK pathway 
[52]. In order to determine the role of MEK-1/2 on induction of IL-10 production 
from Helicobacter-activated B cells, whole cells extracts of ctrl B, B+H.f., 
Helicobacter-activated IL-10- B cells and IL-10+ B cells were examined for 
phosphorylation of MEK-1/2 by Western Blotting (Fig. 3.7).  
B 
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Figure 3.7:  Investigation of phosphorylation levels of MEK-1/2. Splenic B cells 
were stimulated with H. felis sonicate for 24 h (B+H.f.). Control B 
(ctrl B) cells did not receive any treatment. Upon addition of PMA 
(50ng/ml) and ionomycin (500ng/ml) during last 5h of 24h-long 
incubation, H. felis-stimulated cells were magnetically separated as 
IL-10– B and IL-10+ B cells. Cells were lysed and whole cell extracts 
were immunoblotted for p-MEK-1/2 and MEK-1/2. Vinculin was used 
as loading control. Western Blotting results (upper panel) are 
representative of three independent experiments (n=3). GraphPad 
Prism 5.0 was used to graph mean levels of MEK-1/2 phosphorylation 
(lower panel).   Statistical   analysis   was   conducted   using   Student’s   t 
test. 
Western Blotting results indicated phosphorylation of MEK-1/2 was significantly 
more B+H.f. cells when compared to ctrl B cells (40% and 30%, respectively). 
Furthermore, MEK-1/2 was significantly more phosphorylated in Helicobacter-
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activated IL-10+ B cells compared to IL-10- B cells (65% and 56%, respectively). 
Phosphorylation percentages were found to be higher in Helicobacter-activated IL-
10– B and IL-10+ B fractions when compared to B+H.f. sample possibly due to the 
induction of these fractions with PMA and ionomycin. This result suggests that 
activation of MEK-1/2 may play a more prominent role in induction of IL-10 
production from Helicobacter-activated B cells. 
3.6.3 The role of p44/42 MAPK (ERK-1/2) on IL-10 production 
Many immune cells such as antigen presenting cells of innate immune system (DCs 
and macrophages), T helper cells and TLR7/8-stimulated primary human B cells 
were found to utilize ERK-1/2 signaling module of MAPK pathway in IL-10 
production [75, 100]. In order to elucidate the role of ERK-1/2 on induction of IL-10 
production from Helicobacter-activated B cells, whole cells extracts of ctrl B, 
B+H.f., Helicobacter-activated IL-10- B cells and IL-10+ B cells were investigated 
for phosphorylation of ERK-1/2 by Western Blotting upon utilizing antibodies 
against total- and phosphorylated forms of ERK-1/2 (Fig. 3.8).  
 
Figure 3.8: Assessment of phosphorylation levels of ERK-1/2. 
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Figure 3.8 (cont’d.): Assessment of phosphorylation levels of ERK-1/2. Splenic B 
cells were stimulated with H. felis sonicate for 24 h (B+H.f.). 
Control B cells (ctrl B) did not receive any treatment. Upon 
addition of PMA (50 ng/ml) and ionomycin (500 ng/ml) 
during last 5 h of 24 h-long incubation, H. felis-stimulated 
cells were magnetically separated as IL-10– B and IL-10+ B 
cells. Cells were lysed and whole cell extracts were 
immunoblotted for phospho- and total-ERK-1/2. Vinculin 
was used as loading control. Western Blotting data (upper 
panel) from one of three independently conducted 
experiments are shown (n=3). GraphPad Prism 5.0 was used 
to graph mean levels of ERK-1/2 phosphorylation obtained 
by densitometric analysis (lower panel). Statistical analysis 
was  conducted  using  Student’s  t test. 
 
According to total- and phospho-ERK-1/2 Western Blotting results, ERK-1/2 
phosphorylation was found to be significantly elevated in B+H.f. cells when 
compared to unstimulated control (from 25% to 50%, respectively). ERK-1/2 was 
found to be highly phosphorylated in both fractions of PMA and ionomycin-
stimulated Helicobacter-activated B cells. Comparison of ERK-1/2 phosphorylation 
between Helicobacter-activated IL-10- B and IL-10+ B samples demonstrated that IL-
10+ B cells had significantly more phosphorylated ERK-1/2 than IL-10- B cells (85% 
and 97%, respectively). PMA and ionomycin induction was the possible reason 
underlying the increase in phosphorylation percentages of Helicobacter-activated IL-
10- B and IL-10+ B compared to B+H.f. cells.  
Considering that ERK-1/2 is a downstream effector of MEK-1/2, the similar trend of 
MEK-1/2 and ERK-1/2 phosphorylation for same samples was expected. And taken 
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together, these results further suggest that activation of MEK-ERK pathway is 
required for induction of IL-10 production from Helicobacter-activated B cells.    
3.6.4 The role of CREB as a downstream effector of MAPK signaling pathway 
on IL-10 production 
As a transcription factor, CREB is known to be a downstream effector of both 
signaling modules (p38 MAPK and ERK-1/2) of MAPK signaling pathway which 
plays an important role in transcription of IL-10 in TLR-stimulated macrophages. 
Activated CREB gets translocated into the nucleus with AP-1 and binds to its 
response element cAMP response element (CRE) to initiate the transcription of IL-10 
gene [75]. In order to determine the role of CREB on induction of IL-10 production 
from Helicobacter-activated B cells, whole cell extracts of ctrl B, B+H.f., 
Helicobacter-activated IL-10- B cells and IL-10+ B cells were investigated for CREB 
phosphorylation via Western Blotting by using antibodies targeted against total- and 
phospho-CREB (phosphorylated at Ser133 residue) (Fig. 3.9).  
 
Figure 3.9: Investigation for phosphorylation levels of CREB. 
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Figure 3.9 (cont’d.):  Investigation for phosphorylation levels of CREB. Splenic B 
cells were stimulated with H. felis sonicate for 24 h (B+H.f.). 
Control B cells (ctrl B) did not receive any treatment. Upon 
addition of PMA (50ng/ml) and ionomycin (500ng/ml) 
during last 5 h of 24 h-long incubation, H. felis-stimulated 
cells were magnetically separated as IL-10– B and IL-10+ B 
cells. Cells were lysed and whole cell extracts were 
immunoblotted for phospho- and total-CREB. Vinculin was 
used as loading control. Western Blotting data (upper panel) 
from one of three independently conducted experiments are 
shown (n=3). GraphPad Prism 5.0 was used to graph mean 
levels of CREB phosphorylation obtained by densitometric 
analysis (lower panel). Statistical analysis was conducted 
using  Student’s  t test. 
Western Blotting results indicated that phosphorylation of CREB was significantly 
decreased in H.felis sonicate-stimulated B cells when compared to untreated control 
(from 40% to 20%, respectively). Comparison of CREB phosphorylation between 
Helicobacter-activated IL-10- B and IL-10+ B samples revealed that CREB 
phosphorylation was significantly elevated from 70% to 95% in IL-10+ B cells. 
Phosphorylation percentages were found to be higher in Helicobacter-activated IL-
10– B and IL-10+ B fractions when compared to B+H.f. sample possibly due to the 
induction of these fractions with PMA and ionomycin prior to magnetic separation. 
The role of additional intracellular signaling pathways acting on activation status of 
CREB may be speculated regarding the reduction of CREB phosphorylation in 
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Helicobacter-stimulated B cells compared to untreated control. These results overall 
suggest involvement of CREB activation in induction of IL-10 production from 
Helicobacter-activated B cells. 
3.6.5 The effect of MEK-1/2 inhibitor (U0126) 
3.6.5.1 The effect of MEK-1/2 inhibitor (U0126) on ERK-1/2 phosphorylation 
MEK-ERK pathway was found to be central for induction of IL-10 production upon 
TLR-stimulation from many immune cell types [75]. Western Blotting results for 
ERK-1/2 phosphorylation (Fig. 3.8) suggested involvement of ERK-1/2 signaling 
module on induction of IL-10 production from Helicobacter-activated B cells. In 
order to identify the role of MEK-ERK pathway on IL-10 production in 
Helicobacter-activated B cells, a specific inhibitor of MEK-1/2 (U0126) was 
utilized. For validating the efficiency of MEK-1/2 inhibitor, its effect on ERK-1/2 
phosphorylation was investigated (Fig. 3.10). 
 
Figure 3.10: Effect of MEK-1/2 inhibitor on phosphorylation of ERK-1/2. 
 60 
 
                         
Figure 3.10 (cont’d.):  Effect of MEK-1/2 inhibitor on phosphorylation of ERK-1/2. 
Murine splenic B cells were either pre-treated with MEK-
1/2  inhibitor  (15  µM)  or  vehicle  control  (DMSO)  for  1  hour  
or left untreated (no inh.). After 1 h, cells were either 
stimulated   with   10   µg/ml H.felis sonicate (B+H.f.) or left 
unstimulated (ctrl B) for 24 h. Cells were lysed and whole 
cell extracts were immunoblotted for phospho- and total-
ERK-1/2. Vinculin was used as loading control. Western 
Blotting data (upper panel) from one of three independently 
conducted experiments are shown (n=3). GraphPad Prism 
5.0 was used to graph mean levels of ERK-1/2 
phosphorylation obtained by densitometric analysis (lower 
panel). n.d. denotes not determined. 
Western Blotting results demonstrated that MEK-1/2 inhibitor totally abrogated 
phosphorylation of ERK-1/2 in H.felis-sonicate treated B cells and untreated 
controls. Since vehicle control (DMSO) did not alter the phosphorylation of ERK-
1/2, it can be claimed that the abrogation of ERK-1/2 phosphorylation was merely 
the effect of used inhibitor. Furthermore, in parallel with previous findings (Fig. 3.8), 
phosphorylation of ERK-1/2 was found to be elevated from 10% to 50% in H.felis 
sonicate treated B cells when compared to untreated controls. These results suggest 
that MEK-1/2 inhibitor was very efficient in blocking MEK-ERK signaling in 
Helicobacter-activated B cells.  
3.6.5.2 The effect of MEK1/2 inhibitor (U0126) on CREB phosphorylation 
Since CREB was known to be a downstream effector of ERK-1/2 [75], the effect of 
MEK-1/2 inhibitor on phosphorylation of CREB was also investigated (Fig. 3.11).  
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Figure 3.11: Effect of MEK-1/2 inhibitor on phosphorylation of CREB. Murine 
splenic B cells were either pre-treated with MEK-1/2 inhibitor (15 
µM)  or  vehicle  control  (DMSO)  for  1  hour  or  left  untreated  (no  inh.).  
After  1  h,  cells  were  either  stimulated  with  10  µg/ml H.felis sonicate 
(B+H.f.) or left unstimulated (ctrl B) for 24 h. Cells were lysed and 
whole cell extracts were immunoblotted for phospho- and total-
CREB. Vinculin was used as loading control. Western Blotting data 
(upper panel) from one of three independently conducted experiments 
are shown (n=3). GraphPad Prism 5.0 was used to graph mean levels 
of CREB phosphorylation obtained by densitometric analysis (lower 
panel).  
According to immunoblotting results, CREB phosphorylation was decreased for both 
ctrl B and B+H.f. samples with the use of MEK-1/2 inhibitor whereas DMSO 
application did not bring about a noticeable change in phosphorylation status of 
CREB except for a slight decrease in ctrl B samples. CREB phosphorylation was not 
totally abrogated with the use of MEK-1/2 inhibitor. This result was expected since it 
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was known that signaling modules other than ERK-1/2 such as p38 MAPK or PI3K 
may act on CREB for activation of this transcription factor [75]. Nevertheless, these 
results also portray the efficiency of MEK-1/2 inhibitor on signaling molecules 
downstream of ERK-1/2.   
3.6.5.3 The effect of MEK-1/2 inhibitor (U0126) on IL-10 secretion 
Following assessment of the efficiency for MEK-1/2 inhibitor at   15   µM  
concentration on blocking MEK-ERK signaling pathway in Helicobacter-activated 
murine splenic B cells, the effect of MEK-1/2 inhibitor on IL-10 production and 
secretion was investigated. In order to determine the role of MEK-ERK pathway on 
IL-10 secretion, culture supernatants of B cells were probed for secreted amounts of 
IL-10 by ELISA (Fig. 3.12).  
 
Figure 3.12:  Effect of MEK-1/2 inhibitor on IL-10 secretion. B cells were either pre-
treated with MEK-1/2 inhibitor (15 µM)  or  vehicle control (DMSO) 
for 1 hour or left untreated (no inh.). After 1 h, cells were either 
stimulated with 10 µg/ml H.felis sonicate (B+H.f.) or left unstimulated 
(ctrl B). Following 24h-long incubation, culture supernatants were 
probed for secreted IL-10 by ELISA. Data are representative of three 
independent experiments (n=3). Results are graphed using GraphPad 
Prism 5.0. Statistical analysis was   conducted   using   Student’s   t test. 
n.s. stands for not significant. 
 63 
 
IL-10 ELISA results (Fig. 3.12) demonstrated that IL-10 secretion was significantly 
reduced in samples treated with MEK-1/2 inhibitor when compared to untreated or 
vehicle (DMSO)-treated controls. No significant change in secreted IL-10 levels was 
observed between samples without inhibitor treatment and samples that were treated 
with vehicle control (DMSO). Moreover, as expected, IL-10 secretion levels were 
found to be significantly elevated (2.5-fold) in B cells stimulated with H.felis 
sonicate when compared to ctrl B samples. DMSO-treated samples displayed a 
similar pattern (with 3-fold increase) for IL-10 secretion. These results suggest the 
requirement of MEK-ERK signaling module of MAPK pathway for IL-10 
production and secretion from Helicobacter-activated B cells. 
3.6.6 The effect of p38 MAPK inhibitor (SB203580) 
3.6.6.1 The effect of p38 MAPK inhibitor (SB203580) on CREB phosphorylation 
p38 MAPK pathway was found to be central for induction of IL-10 production upon 
TLR-stimulation from many immune cell types such as macrophages or DCs [75]. 
Moreover, the requirement for p38 MAPK signaling for induction of IL-10 
production from TLR4- or TLR9-stimulated murine B cells was recently shown. 
Even though Western Blotting results for p38 MAPK phosphorylation (Fig. 3.6) 
suggested involvement of p38 MAPK signaling module in Helicobacter-activated 
IL-10- B cells rather than IL-10+ B cells, the role of p38 MAPK on induction of IL-
10 production from Helicobacter-activated B cells was further investigated with the 
use of specific chemical inhibitor (SB203580) of p38 MAPK signaling. The effect of 
p38 MAPK inhibitor (SB203580) on CREB phosphorylation was investigated since 
SB203580 did not affect the phosphorylation status of p38 MAPK but was known to 
block signaling downstream of p38 MAPK and CREB was known to be a 
downstream effector of p38 MAPK module of MAPK signaling pathway [51, 75] 
(Fig. 3.13). 
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Figure 3.13: Effect of p38 MAPK inhibitor on phosphorylation of CREB. Murine 
splenic B cells were either pre-treated with p38 MAPK inhibitor (15 
µM)  or  vehicle  control  (DMSO)  for  1  hour  or  left  untreated  (no  inh.). 
After  1  h,  cells  were  either  stimulated  with  10  µg/ml H.felis sonicate 
(B+H.f.) or left unstimulated (ctrl B) for 24 h. Cells were lysed and 
whole cell extracts were immunoblotted for phospho- and total-
CREB. Vinculin was used as loading control. Western Blotting data 
(upper panel) from one of three independently conducted experiments 
are shown (n=3). GraphPad Prism 5.0 was used to graph mean levels 
of CREB phosphorylation obtained by densitometric analysis (lower 
panel). Statistical analysis was conducted  using  Student’s  t test.  
According to Western Blotting results, p38 MAPK inhibitor was found to reduce 
phosphorylation of CREB in both ctrl B (from 60% to 25%) and B+H.f (from 40% to 
20%) samples whereas DMSO control did not alter the phosphorylation of CREB 
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noticeably (Fig. 3.13). Moreover, in parallel with previous findings (Fig. 3.9), 
compared to untreated control, CREB phosphorylation level was decreased in H.felis 
sonicate-treated B cells (from 60% to 40%, respectively). Samples pre-treated with 
DMSO were found to follow the same trend for CREB phosphorylation with slight 
decrease compared to inhibitor-free samples. CREB phosphorylation was not totally 
abrogated with the use of p38 MAPK inhibitor. This result was expected since it was 
known that signaling modules other than p38 MAPK such as ERK-1/2 or PI3K may 
act on activation of CREB [75]. These results suggest that p38 MAPK inhibitor was 
efficient enough to interfere with p38 MAPK downstream signaling.  
3.6.6.2 The effect of p38 MAPK inhibitor (SB203580) on IL-10 secretion 
Following validation of p38  MAPK  inhibitor’s efficiency  at  10  µM  concentration  on  
murine splenic B cells, culture supernatants of B cell samples were probed for 
quantitative determination of IL-10 secretion by ELISA (Fig. 3.14).  
 
Figure 3.14:  Effect of p38 MAPK inhibitor on IL-10 secretion. B cells were either 
pre-treated with p38 MAPK inhibitor (10 µM)   or   vehicle   control  
(DMSO) for 1 hour or left untreated (no inh.). After 1 h, cells were 
either stimulated with 10 µg/ml H.felis sonicate (B+H.f.) or left 
unstimulated (ctrl B). Following 24h-long incubation, culture 
supernatants were probed for secreted IL-10 by ELISA. Data are 
representative of three independent experiments (n=3). Results are 
graphed using GraphPad Prism 5.0. Statistical analysis was conducted 
using  Student’s  t test. n.s. denotes not significant. 
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IL-10 ELISA results demonstrated that IL-10 secretion was not significantly altered 
in samples treated with p38 MAPK inhibitor when compared to their inhibitor-free 
control samples either pre-treated with vehicle control (DMSO) or not. A comparison 
between ctrl B and B+H.f. samples revealed significant elevation (2-fold) of secreted 
IL-10 levels in B+H.f. samples either pre-treated with DMSO or not. These results 
suggested that p38 MAPK signaling module of MAPK pathway was not required for 
IL-10 production and secretion from Helicobacter-activated B cells.  
3.7 The Role of PI3K Pathway on IL-10 Production From Helicobacter-
stimulated B Cells 
3.7.1 The role of Akt on IL-10 production 
PI3K pathway was found to be involved in induction of IL-10 from macrophages. 
Phosphorylation, therefore activation of Akt, the key player protein kinase of PI3K 
pathway, was found to be required for IL-10 production from TLR-stimulated 
macrophages [75]. In order to elucidate the role of PI3K pathway on induction of IL-
10 production from Helicobacter-activated B cells, phosphorylation of Akt was 
investigated in whole cell extracts of ctrl B, B+H.f., Helicobacter-activated IL-10- B 
cells and IL-10+ B samples using antibodies against total and phosphorylated forms 
of Akt (Fig. 3.15).  
 
Figure 3.15: Assessment of phosphorylation levels of Akt. 
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Figure 3.15 (cont’d.):  Assessment of phosphorylation levels of Akt. Splenic B cells 
were stimulated with H.felis sonicate for 24 h (B+H.f.). 
Control B cells (ctrl B) did not receive any treatment. Upon 
addition of PMA (50 ng/ml) and ionomycin (500 ng/ml) 
during last 5 h of 24 h-long incubation, H.felis-stimulated 
cells were magnetically separated as IL-10– B and IL-10+ B 
cells. Cells were lysed and whole cell extracts were 
immunoblotted for phospho- and total-Akt. Vinculin was 
used as loading control. Western Blotting data (upper 
panel) from one of three independently conducted 
experiments are shown (n=3). GraphPad Prism 5.0 was 
used to graph mean levels of ERK-1/2 phosphorylation 
obtained by densitometric analysis (lower panel). Statistical 
analysis  was  conducted  using  Student’s  t test.              
Western Blotting results indicated that Akt was significantly more phosphorylated in 
H.felis-stimulated B cells (B+H.f.) cells when compared to unstimulated ctrl B cells 
(30% and 20%, respectively). Comparison of Akt phosphorylation between 
Helicobacter-activated IL-10– B and IL-10+ B cells revealed that Akt was 
significantly more phosphorylated in IL-10– B than IL-10+ B cells (60% and 40%, 
respectively). Phosphorylation percentages were found to be higher in Helicobacter-
activated IL-10– B and IL-10+ B fractions when compared to B+H.f. sample possibly 
due to the induction of these fractions with PMA and ionomycin. This result suggests 
that, similar to p38 MAPK, activation of Akt may play a more prominent role in 
Helicobacter-activated IL-10- B cells rather than IL-10+ B. 
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3.7.2 The role of GSK-3β  on  IL-10 production 
Activated Akt phosphorylates, therefore inactivates GSK-3β.   Active   GSK-3β   is  
known to inhibit binding of CREB and AP-1 to DNA and initiation of IL-10 
expression [75]. In order to figure out the role of PI3K pathway on induction of IL-
10 production from Helicobacter-activated B cells, phosphorylation of GSK-3β,  
downstream effector of Akt, was also investigated (Fig. 3.16).  
 
 
Figure 3.16: Investigation for phosphorylation levels of GSK-3β. Splenic B cells 
were stimulated with H. felis sonicate for 24 h (B+H.f.). Control B 
cells (ctrl B) did not receive any treatment. Upon addition of PMA (50 
ng/ml) and ionomycin (500 ng/ml) during last 5 h of 24 h-long 
incubation, H. felis-stimulated cells were magnetically separated as 
IL-10– B and IL-10+ B cells. Cells were lysed and whole cell extracts 
were immunoblotted for phospho- and total-GSK-3β.   Vinculin   was  
used as loading control. Western Blotting data (upper panel) from one 
of three independently conducted experiments are shown (n=3). 
GraphPad Prism 5.0 was used to graph mean levels of GSK-3β  
phosphorylation obtained by densitometric analysis (lower panel). 
Statistical  analysis  was  conducted  using  Student’s  t test. 
B 
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According to Western Blotting results, phosphorylation of GSK-3β  was  significantly  
elevated in H.felis-stimulated B cells (B+H.f.) cells when compared to unstimulated 
ctrl B cells (90% and 50%, respectively). Phosphorylation of GSK-3β   was  
significantly reduced from 80% to 40% in Helicobacter-activated IL-10+ B cells 
(~40%) when compared to IL-10- B cells. Phosphorylation status of GSK-3β  was  
found to be similar to Akt phosphorylation status. This was expected since GSK-3β  
is a downstream effector of Akt. These results suggest that GSK-3β  gets  inactivated  
in B cells upon Helicobacter felis sonicate-stimulation. On the other hand, 
Helicobacter-activated IL-10+ B cells were found to have more active GSK-3β  
compared to IL-10– B cells. Taken together with Akt phosphorylation status (Fig. 
3.15), these results collectively suggest involvement of PI3K signaling pathway in 
Helicobacter-activated IL-10- B cells rather than IL-10+ B cells. 
3.7.3 The role of CREB as a downstream effector of PI3K signaling pathway on 
IL-10 production 
CREB is a downstream effector of both MAPK and PI3K signaling pathways. CREB 
is known to play an important role in expression of IL-10 from TLR-stimulated 
macrophages [75]. Western Blotting data on phosphorylation of CREB is shown in 
Figure 3.9. Western Blotting results indicated that phosphorylation of CREB was 
significantly decreased from 40% to 20% in H.felis sonicate-stimulated B cells when 
compared to untreated control. Comparison of CREB phosphorylation between 
Helicobacter-activated IL-10- B and IL-10+ B samples revealed that CREB 
phosphorylation was significantly elevated from approximately 70% to 90% in IL-
10+ B cells.  
GSK-3β   is   rendered   inactive  when phosphorylated and when unphosphorylated, in 
its active form, it is known to inhibit binding of CREB to DNA and initiate 
transcription of related response genes [75, 88]. Hence, phosphorylation of GSK-3β  
means inactivation of GSK-3β,  which  in  turn  leads to activation and phosphorylation 
of CREB. According to Western Blotting results of GSK-3β  phosphorylation (Fig. 
3.16), GSK-3β   seems   to   be   more   active   in   Helicobacter-activated IL-10+ B cell 
subset since it is less phosphorylated when compared to IL-10- B subset. However, 
contrary to expectations based on GSK-3β  phosphorylation  results,  phosphorylation  
of CREB is significantly elevated in Helicobacter-activated IL-10+ B subset. This 
 70 
 
discrepancy may be   explained   by   CREB’s   inhibitory   second   phosphorylation   at 
Ser129 by active GSK-3β   [87].  Since   the  antibody   that  was  used   in   this   study  was  
produced to recognize CREB phosphorylated merely at Ser133, but inactive CREB is 
also phosphorylated at Ser133 along with Ser129, investigating phosphorylation of 
CREB by only checking for p-CREB (Ser133) may not be enough to assess CREB 
activity. Moreover, many other signaling pathways may regulate activation of CREB 
other than GSK-3β  such  as  ERK-1/2 module. It may be speculated that the effect of 
ERK-1/2 on activation status of CREB is dominant over that of GSK-3β.  
3.7.4 The effect of PI3K inhibitor (LY294002)  
3.7.4.1 The effect of PI3K inhibitor (LY294002) on Akt phosphorylation 
PI3K pathway was found to be one of the signaling pathways utilized in induction of 
IL-10 from TLR-stimulated macrophages [75]. Even though Western Blotting results 
for phosphorylation of Akt and GSK-3β   (Figures 3.15 and 3.16, respectively) 
suggested involvement of PI3K signaling pathway in Helicobacter-activated IL-10- B 
cells rather than IL-10+ B cells, the role of PI3K signal transduction pathway on 
induction of IL-10 production from Helicobacter-activated B cells was further 
investigated with the use of specific chemical inhibitor (LY294002) of PI3K 
signaling. For this purpose, initially the effect of PI3K inhibitor (LY294002) on Akt 
phosphorylation was investigated (Fig. 3.17). 
 
Figure 3.17: Effect of PI3K inhibitor on phosphorylation of Akt. 
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Figure 3.17 (cont’d.):  Effect of PI3K inhibitor on phosphorylation of Akt. Murine 
splenic B cells were either pre-treated with PI3K inhibitor 
(15   µM)   or   vehicle   control   (DMSO)   for   1   hour   or   left  
untreated (no inh.). After 1 h, cells were either stimulated 
with  10  µg/ml H.felis sonicate (B+H.f.) or left unstimulated 
(ctrl B) for 24 h. Cells were lysed and whole cell extracts 
were immunoblotted for phospho- and total-Akt. Vinculin 
was used as loading control. Western Blotting data (upper 
panel) from one of three independently conducted 
experiments are shown (n=3). GraphPad Prism 5.0 was 
used to graph mean levels of Akt phosphorylation obtained 
by densitometric analysis (lower panel). n.d. stands for not 
determined. 
  
Total abrogation of Akt phosphorylation was observed in PI3K inhibitor-treated 
samples whereas phosphorylation of Akt was not affected in samples pre-treated with 
vehicle control (DMSO). Moreover, in parallel with previous findings, an elevation 
in Akt phosphorylation from 20% to 40% was evident for B+H.f. samples when 
compared to ctrl B samples. A similar trend in phosphorylation of Akt was also 
observed in samples pre-treated with DMSO. These results suggest that PI3K 
inhibitor was very efficient in blocking PI3K signaling in Helicobacter-activated B 
cells. 
3.7.4.2 The effect of PI3K inhibitor (LY294002) on IL-10 secretion 
Following validation of the efficiency for PI3K inhibitor  at  15  µM  concentration  on  
blocking PI3K signaling pathway in Helicobacter-activated murine splenic B cells, 
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the effect of PI3K inhibitor on IL-10 production and secretion was investigated. In 
order to elucidate the role of PI3K pathway on IL-10 secretion, culture supernatants 
of B cells were probed for secreted amounts of IL-10 by ELISA (Fig. 3.18).  
 
Figure 3.18: Effect of PI3K inhibitor on IL-10 secretion. B cells were either pre-
treated with PI3K inhibitor  (15  µM)  or  vehicle  control  (DMSO)  for  1  
hour or left untreated (no inh.). After 1 h, cells were either stimulated 
with 10 µg/ml H.felis sonicate (B+H.f.) or left unstimulated (ctrl B). 
Following 24 h-long incubation, culture supernatants were probed for 
secreted IL-10 by ELISA. Data are representative of three independent 
experiments (n=3). Results are graphed using GraphPad Prism 5.0. 
Statistical  analysis  was  conducted  using  Student’s  t test. n.s. stands for 
not significant. 
IL-10 ELISA results demonstrated that secreted IL-10 levels did not significantly 
change in Helicobacter-activated B cells pre-treated with PI3K inhibitor when 
compared to untreated or DMSO pre-treated B cells. Furthermore, compared to ctrl B 
samples, significant increase (2.5-fold) of secreted IL-10 levels was observed in 
B+H.f. samples either pre-treated with DMSO or not. These results suggest that PI3K 
signaling pathway was not required for induction of IL-10 production from 
Helicobacter-activated B cells. 
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3.8 The Role of Canonical NF-κB   Pathway on IL-10 Production From 
Helicobacter-stimulated B Cells 
3.8.1 The role of p65 subunit of NF-κB  on  IL-10 production 
p65 subunit of NF-κB   was   found   to   interact   with   IL-10 coding DNA region in 
murine macrophages stimulated by LPS for IL-10 production [92]. The role of p65 
subunit on IL-10 production from Helicobacter-activated B cells was not known. In 
order to determine the phosphorylation of p65 subunit of NF-κB  signaling  pathway,  
whole cell extracts of ctrl B, B+H.f., Helicobacter-activated IL-10- B and IL-10+ B 
cells were used as samples for Signaling Nodes PathScan ELISA (explained in detail 
in section 2.2.13) which detects p65 protein when phosphorylated at Ser536 residue 
(Fig 3.19).  
 
Figure 3.19:  Investigation for phosphorylation of p65 subunit of canonical NF-κB  
signaling pathway. Splenic B cells were stimulated with H. felis 
sonicate for 24 h (B+H.f.). Control B cells (ctrl B) did not receive any 
treatment. Upon addition of PMA (50 ng/ml) and ionomycin (500 
ng/ml) during last 5 h of 24 h-long incubation, H. felis-stimulated cells 
were magnetically separated as IL-10– B and IL-10+ B cells. Cells 
lysates were assayed at a protein concentration of 0.15 mg/ml using 
the PathScan Signaling Nodes Multi-Target Sandwich ELISA Kit 
#7272 (Cell Signaling Technology, Inc.) as per manufacturer's 
instructions. The absorbance readings of biological duplicate samples 
at 450 nm were graphed using GraphPad Prism 5.0. Statistical 
analysis   was   conducted   using   Student’s   t test. n.s. denotes not 
significant. 
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According to preliminary PathScan ELISA results, no significant change in 
phosphorylation status of p65 subunit among ctrl B, B+H.f., Helicobacter-activated 
IL-10- B cell or IL-10+ B cell samples was observed. These results suggest 
Helicobacter--stimulated B cells do not utilize canonical pathway of NF-κB for 
induction of IL-10 production.  
3.8.2 The effect of NF-κB  inhibitor (PDTC) 
3.8.2.1 The effect of NF-κB  inhibitor  (PDTC)  on  IL-10 secretion 
In order to further determine the role of canonical pathway of NF-κB on induction of 
IL-10 production from Helicobacter-activated B cells, a chemical inhibitor of 
canonical NF-κB   pathway (PDTC) was used. The effect of blockage of NF-κB  
canonical pathway on IL-10 secretion was determined by IL-10 ELISA (Fig. 3.20). 
 
Figure 3.20:  Effect of NF-κB inhibitor on IL-10 secretion. B cells were either pre-
treated with NF-κB inhibitor (30 µM)  or  vehicle  control  (DMSO)  for  
1 hour or left untreated (no inh.). After 1 h, cells were either 
stimulated with 10 µg/ml  H.felis sonicate (B+H.f.) or left 
unstimulated (ctrl B). Following 24 h-long incubation, culture 
supernatants were probed for secreted IL-10 by ELISA. Data are 
representative of three independent experiments (n=3). Results are 
graphed using GraphPad Prism 5.0. Statistical analysis was conducted 
using  Student’s  t test. n.s. stands for not significant. 
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IL-10 ELISA results demonstrated that IL-10 secretion levels did not significantly 
change in the samples treated with PDTC when compared to their inhibitor-free 
control samples either DMSO-treated or not. A comparison between ctrl B and 
B+H.f. samples revealed significant increase (2-fold) of secreted IL-10 levels in 
B+H.f. samples either pre-treated with DMSO or not.  These results suggest that 
canonical pathway of NF-κB was not required for IL-10 production and secretion 
from Helicobacter-activated B cells.  
3.9 The Effect of MEK-1/2 Inhibitor (U0126) on TLR4 or TLR9-stimulated IL-
10 Production 
It was recently shown that ERK-1/2 module of MAPK signaling pathway was not 
required for IL-10 production from TLR4- or TLR9-stimulated murine B cells [80]. 
In order to investigate the involvement of ERK-1/2 module of MAPK signaling in 
IL-10 production and secretion from TLR4 or TLR9-stimulated B cells, MEK-1/2 
inhibitor (U0126) was used and culture supernatants of B cells were probed for IL-10 
by ELISA (Fig.3.21).  
 
Figure 3.21: Effect of MEK-1/2 inhibitor on TLR4- or TLR9-stimulated IL-10 
secretion. 
 76 
 
Figure 3.21 (cont’d.): Effect of MEK-1/2 inhibitor on TLR4- or TLR9-stimulated IL-
10 secretion. B cells were either pre-treated with MEK-1/2 
inhibitor   (15  µM)  or   vehicle   control   (DMSO) for 1 hour or 
left untreated (no inh.). After 1 h, cells were either stimulated 
with 10 µg/ml LPS (B+LPS),  5  µg/ml CpG (B+CpG) or left 
unstimulated (ctrl B). Following 48 h-long incubation, 
culture supernatants were probed for secreted IL-10 by 
ELISA. All samples were used as biological duplicates. 
Results are graphed using GraphPad Prism 5.0. Statistical 
analysis was conducted  using  Student’s   t test. n.s. stands for 
not significant. 
Preliminary IL-10 ELISA results indicated that IL-10 secretion levels did not 
significantly change in MEK-1/2 inhibitor-treated LPS or CpG-stimulated samples 
when compared to untreated or DMSO-treated samples. Besides, IL-10 secretion 
levels were found to be significantly increased in both TLR4-stimulated and TLR9-
stimulated B cells when compared to unstimulated controls either DMSO-treated or 
not. LPS stimulation elicited more IL-10 secretion (15-fold) from B cells when 
compared to CpG stimulation (8-fold). These results are correlated with the findings 
of Mion and colleagues [80] and they suggest that IL-10 production from TLR4- or 
TLR9-stimulated B cells did not require ERK-1/2 module of MAPK pathway.   
3.10 The Effect of p38 MAPK Inhibitor (SB203580) on TLR4 or TLR9-
stimulated IL-10 Production 
Recently, the involvement of p38 MAPK signaling in IL-10 production from TLR4- 
or TLR9-stimulated B cells has been shown [80]. In order to confirm the 
involvement of p38 MAPK module of MAPK signaling in TLR-mediated IL-10 
production and secretion, TLR4 ligand LPS and TLR9 ligand CpG were chosen as 
stimulants which were known to induce IL-10 production from B cells [80]. For 
investigation of the role of p38 MAPK signaling module in IL-10 production from 
LPS or CpG-stimulated B cells, p38 MAPK inhibitor (SB203580) was used and 
culture supernatants were monitored for IL-10 secretion by ELISA (Fig. 3.22).  
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Figure 3.22: Effect of p38 MAPK inhibitor on TLR4- or TLR9-stimulated IL-10 
secretion. B cells were either pre-treated with p38 MAPK inhibitor 
(10 µM)  or  vehicle   control   (DMSO)   for  1  hour  or   left   untreated   (no  
inh.).   After   1   h,   cells   were   either   stimulated   with   10   µg/ml LPS 
(B+LPS),   5   µg/ml CpG (B+CpG) or left unstimulated (ctrl B). 
Following 48 h-long incubation, culture supernatants were probed for 
secreted IL-10 by ELISA. All samples were used as biological 
duplicates. Results are graphed using GraphPad Prism 5.0. Statistical 
analysis   was   conducted   using   Student’s   t test. n.s. denotes not 
significant. 
According to preliminary IL-10 ELISA results, both TLR4- and TLR9-stimulation 
resulted in significantly elevated IL-10 secretion from B cells when compared to 
unstimulated control. Furthermore, IL-10 secretion was found to be significantly 
reduced in TLR4 and TLR9-stimulated samples which were pre-treated with p38 
MAPK inhibitor when compared to untreated and vehicle control (DMSO)-treated 
ones. When compared to CpG stimulation (8-fold), more IL-10 was found to be 
secreted from B cells as a result of LPS stimulation (15-fold).  
Taken together with the results for the effect of MEK-1/2 inhibitor on TLR4- or 
TLR9- stimulated IL-10 production (Fig. 3.21), these findings were in line with 
recent findings of Mion and colleagues and suggest the involvement of p38 MAPK 
module rather than ERK-1/2 module of MAPK signaling pathway in induction of IL-
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10 production from TLR4- or TLR9-stimulated B cells. Considering that ERK-1/2 
was found to be required for induction of IL-10 production from TLR2-stimulated B 
cells, these findings collectively can be interpreted as IL-10 production from B cells 
stimulated by different TLR ligands may require differential intracellular signaling 
pathways.  
3.11 The Role of STAT3 on IL-10 Production 
IL-10 exerts its effects on immune cells by binding to its receptor complex. Binding 
of IL-10 to its receptor complex brings about phosphorylation of STAT3 via 
JAK/STAT signaling pathway [23, 61-63]. IL-10 is known to induce its own 
production via interaction with its own receptor complex and activation of STAT3 by 
phosphorylation in TLR-stimulated macrophages [75]. Moreover, activation of 
STAT3 along with ERK is also found to be required for IL-10 production from T 
helper 17 (Th17) cells [75] and from TLR7/8-stimulated human primary B cells 
[100]. The involvement of STAT3 in IL-10 production from Helicobacter-stimulated 
B cells was not known. In order to determine the role of STAT3 on induction of IL-
10 production from Helicobacter-stimulated B cells, whole cell extracts of ctrl B, 
B+H.f., Helicobacter-activated IL-10- B cells and IL-10+ B cells were used as 
samples for Cell Signaling Signaling Nodes PathScan ELISA which detects STAT3 
protein when phosphorylated at Tyr705 residue (Fig. 3.23). 
 
Figure 3.23: Investigation for phosphorylation of STAT3. 
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Figure 3.23 (cont’d.):  Investigation for phosphorylation of STAT3. Splenic B cells 
were stimulated with H. felis sonicate for 24 h (B+H.f.). 
Control B cells (ctrl B) did not receive any treatment. Upon 
addition of PMA (50 ng/ml) and ionomycin (500 ng/ml) 
during last 5 h of 24 h-long incubation, H. felis-stimulated 
cells were magnetically separated as IL-10– B and IL-10+ B 
cells. Cells lysates were assayed at a protein concentration 
of 0.15 mg/ml using the PathScan Signaling Nodes Multi-
Target Sandwich ELISA Kit #7272 (Cell Signaling 
Technology, Inc.) as per manufacturer's instructions. The 
absorbance readings of biological duplicate samples at 450 
nm were graphed using GraphPad Prism 5.0. Statistical 
analysis  was   conducted   using  Student’s   t test. n.s. denotes 
not significant. 
According to preliminary PathScan ELISA results, no significant change in STAT3 
phosphorylation status was observed between ctrl B and B+H.f. samples. On the 
other hand, comparison between Helicobacter-activated IL-10- B and IL-10+ B cell 
samples revealed that STAT3 was significantly more phosphorylated, therefore 
activated in Helicobacter-activated IL-10+ B cells. These preliminary results 
suggested involvement of STAT3 signaling in IL-10 production and a potential role 
for IL-10 in inducing its own production via STAT3-dependent pathway in an 
autocrine/paracrine manner.   
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4. DISCUSSION AND CONCLUSION 
 
Examination of potential intracellular signal transduction pathways that may have a 
role in induction of IL-10 production from Helicobacter-stimulated B cells was the 
main research focus of this study.  
Helicobacter pylori has causative role in many gastric malignancies such as chronic 
gastritis, peptic ulcer and gastric adenocarcinoma. Even though half of the world 
population is infected with the pathogen, only a minority develop gastric 
malignancies. The asymptomacity of majority of infected population can be 
attributed to existence of regulatory cells which suppress excessive pro-inflammatory 
response elicited against bacteria. An anti-inflammatory cytokine, IL-10 has been 
shown to possess suppressive and immune regulatory functions. A subset of B cells 
has recently been shown to produce IL-10 in response to Helicobacter-infection. 
Murine B cells sense Helicobacter felis (a counterpart of Helicobacter pylori which 
has higher immunogenicity for mice) in TLR2-dependent manner. TLR2-MyD88-
dependent pathway has designated role in IL-10 production from Helicobacter-
activated B cells [18]. Even though TLR-mediated IL-10 production pathways were 
well-characterized for macrophages, dendritic cells and T cells [75], intracellular 
signal transduction pathway(s) leading to IL-10 production and secretion from 
TLR2-stimulated B cells were not elucidated.  
For examination of intracellular pathways, naive B cells obtained from spleen of 
C57BL/6 were stimulated with Helicobacter felis-sonicate in order to elicit IL-10 
production and secretion from B cells as implicated by intracellular IL-10 flow 
staining (Fig. 3.3) and IL-10 ELISA (Fig. 3.4). Fractions of IL-10– B cells and IL-10+ 
B cells from Helicobacter-stimulated B cells were obtained by magnetic separation 
upon PMA and ionomycin addition. Then, phosphorylation of certain kinases that 
take part in fundamental intracellular signaling pathways were investigated in naive 
B cells (ctrl B), Helicobacter felis sonicate-treated B cells (B+H.f.), Helicobacter- 
activated IL-10- B cells and IL-10+ B cells. Investigated kinases were p38 MAPK, 
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MEK-1/2, ERK-1/2 of MAPK pathway, Akt, GSK-3β  of  PI3K  pathway,  CREB  of  
both pathways and p65 of NF-κB  canonical  signaling  pathway.  These  kinases  were  
chosen for investigation since previous studies indicated their involvement in TLR-
mediated IL-10 production from many immune cell types such as macrophages, DCs 
and T helper subsets [75]. 
A comparison between Helicobacter-activated IL-10- B and IL-10+ B cells regarding 
phosphorylation of signaling molecules of MAPK pathway indicated significantly 
elevated phosphorylation of both MEK-1/2 (Fig. 3.7) and its downstream effector 
ERK-1/2 (Fig. 3.8) in IL-10+ B cells. On the other hand, phosphorylation of p38 
MAPK was found to be decreased in IL-10+ B cells (Fig. 3.6). Significant increase in 
phosphorylation of CREB was observed for IL-10+ B cells (Fig. 3.9). Since MEK-1/2 
and ERK-1/2 are kinases of ERK-1/2 module of MAPK pathway, increase in 
phosphorylation, therefore activation of both kinases suggested a prominent role for 
MEK-ERK signaling pathway in IL-10 production. Moreover, it is worth noting that 
comparison of the ctrl B and B+H.f. samples demonstrated similar trends in 
phosphorylation of relevant kinases. Significant increase in phosphorylation of both 
MEK-1/2 and ERK-1/2 and a significant decrease of p38 MAPK phosphorylation 
was observed for B+H.f. This similarity in phosphorylation trend was expected given 
the results of intracellular staining for IL-10 in ctrl B and B+H.f. samples (Fig. 3.3). 
According to those results, more than 60% of Helicobacter-activated B cells were 
found to be producing IL-10. Furthermore, higher phosphorylation levels of 
Helicobacter-activated IL-10- B and IL-10+ B cells compared to total B cells 
stimulated by H.felis sonicate (B+H.f.) may be attributed to PMA and ionomycin 
treatment these cells received before magnetic separation.  
Use of inhibitors blocking MAPK pathway-specific kinases (p38 MAPK inhibitor 
and MEK-1/2 inhibitor) revealed that inhibition of p38 MAPK signaling did not 
result in reduction of IL-10 secretion from Helicobacter-activated B cells (Fig. 3.14), 
whereas IL-10 secretion was significantly decreased when MEK-ERK signaling was 
blocked with MEK-1/2 inhibitor (Fig. 3.12). Taken together with phosphorylation 
status of MAPK-pathway-specific kinases, these results suggest a more prominent 
role for p38 MAPK module in IL-10- B cells rather than IL-10+ B. Most importantly, 
these results also indicate the involvement of MEK-ERK signaling module of MAPK 
pathway in IL-10 production and secretion from Helicobacter-activated B cells.  
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When phosphorylation of signaling molecules of PI3K pathway were scrutinized, 
significant decrease in phosphorylation of both Akt and its downstream effector 
GSK-3β   in  Helicobacter-activated IL-10+ B cells compared to IL-10- B cells was 
observed (Figures 3.15 and 3.16, respectively). Phosphorylation of both Akt and 
GSK-3β   was   found   to   be   significantly   increased in B+H.f. samples compared to 
unstimulated controls. Based on these results, it can be claimed that Helicobacter 
felis sonicate brings about an activation of PI3K pathway through phosphorylation of 
both Akt and its downstream effector GSK-3β.  However,  this  activation seems to be 
more prominent in IL-10- B subset when compared to IL-10+ B cell subsets. Since 
the most eminent distinction between these subsets is their IL-10 production 
capacity, it would not be wrong to assume that PI3K/Akt pathway seems to play a 
rather more significant role in IL-10- B cell subset. Consistent with these findings, 
abrogation of PI3K/Akt signaling with PI3K inhibitor did not significantly alter IL-
10 secretion from Helicobacter-activated B cells. Taken together, these results 
suggest phosphorylation Akt was not required for IL-10 production and secretion 
from Helicobacter-activated B cells.  
As a downstream effector for both MAPK and PI3K signaling pathways, 
phosphorylation of CREB was found to be significantly increased in Helicobacter-
activated IL-10+ B cell subset when compared to IL-10- B cells. Induction of IL-10 
production by CREB activation was shown in literature in many immune cell types 
such as macrophages and DCs (Fig. 1.13). Thus, elevated phosphorylation of CREB 
in Helicobacter-activated IL-10+ B cell subset may affirm CREB’s  designated  role  in  
IL-10 production also from TLR2-stimulated B cells. However, significant decrease 
of CREB phosphorylation in total B cells stimulated with Helicobacter felis sonicate 
compared to unstimulated B cells was observed (Fig. 3.9) Since GSK-3β is 
significantly more phosphorylated, therefore inactivated in B+H.f. compared to ctrl B 
samples, decrease of CREB phosphorylation in this sample cannot be attributed to 
GSK-3β activity. This result suggests involvement of other signaling pathways 
acting on activation status of CREB other than MAPK and PI3K pathways.  
GSK-3β  seems  to  be  more  active  in  Helicobacter-activated IL-10+ B cell subset since 
it is less phosphorylated when compared to IL-10- B subset (Fig. 3.16). In contrast, 
phosphorylation of CREB is found to be elevated in Helicobacter-activated IL-10+ B 
subset (Fig. 3.9). CREB’s   inhibitory   second   phosphorylation   at   Ser129 by active 
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GSK-3β   may be proposed as an explanation for this discrepancy. CREB gets 
activated by phosphorylation at Ser133 residue, but gets inactivated by a secondary 
phosphorylation at Ser129 by active GSK-3β [87]. The antibody used in this study, 
which only detects CREB when phosphorylated at Ser133, may not truly reflect 
activation status of CREB. Moreover, the effect of other signaling pathways such as 
ERK-1/2 signaling module on CREB activation may be dominant over the effect of 
GSK-3β. Moreover, activated CREB is known to be translocated into nucleus upon 
phosphorylation at Ser133 [75]. Translocation of phosphorylated CREB can be 
monitored by immunofluorescence in order to confirm involvement of active CREB 
in induction of IL-10 production. 
Besides, there are many transcription factors downstream of fundamental 
intracellular pathways [75]. One or more of these transcription factors other than 
CREB together or alone can induce transcription of IL-10 from Helicobacter-
activated IL-10+ B cells. Phosphorylation of other transcription factors such as ELK-
1, AP-1, c-FOS, c-JUN can also be investigated in order to determine their 
contribution in IL-10 production. Furthermore, MAPKAPKs activated exclusively by 
ERK-1/2 signaling module (RSKs) and downstream transcription factor MAF (which 
was shown to be of critical importance in IL-10 induction from macrophages and T 
helper subsets [75]) can also be investigated (Fig. 1.7). 
Phosphorylation of p65 subunit was found to be unaffected in murine B cells upon 
Helicobacter felis sonicate stimulation (Fig. 3.19). Accordingly, inhibition of   IκB  
degradation by a chemical inhibitor did not bring about a fluctuation in IL-10 
secretion (Fig. 3.20). These results suggest that TLR2-stimulated IL-10 induction 
was not maintained through canonical pathway of NF-κB.  These findings are in line 
with association of pro-inflammatory cytokine production by canonical pathway of 
NF-κB  and  IL-10’s  inhibitory  effect on p50/p65 heterodimer [74]. These results also 
correlate with recent findings of Liu and colleagues [100] that attribute a dispensable 
role for canonical NF-κB   pathway   in   IL-10 induction from human B cells upon 
TLR7/8 stimulation. Investigating the involvement of p50 subunit or non-canonical 
pathway can be intriguing since recent research on LPS-stimulated primary murine 
macrophages indicated the role of p50/p50 homodimer in IL-10 production [93].      
Although it needs to be further confirmed with at least two more independent 
experiments, preliminary findings regarding STAT3 phosphorylation revealed a 
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significant increase of STAT3 phosphorylation in Helicobacter-activated IL-10+ B 
compared to IL-10- B cell subset even though there was no significant change in 
STAT3 phosphorylation between ctrl B and B+H.f. samples (Fig. 3.23). Elevation of 
STAT3 phosphorylation can suggest involvement of STAT3 activation in induction 
of IL-10 production. Moreover, IL-10 is known to induce its own production through 
IL-10R-STAT3-dependent signaling [75]. Hence, a mechanism can be proposed for 
secreted IL-10 inducing its own production from Helicobacter-activated IL-10+ B 
cell subset in an autocrine-paracrine manner. Further studies to elucidate the role of 
STAT3 signaling on induction of IL-10 production from Helicobacter-activated B 
cells with the use of STAT3-specific inhibitors may be of importance.  
The role of MAPK signaling pathway modules in IL-10 production from B cells 
upon stimulation of TLRs other than TLR2 was also investigated in this study. 
Utilization of specific inhibitors of p38 MAPK and MEK-1/2 revealed that TLR4- 
and TLR9-stimulated IL-10 induction from murine B cells was associated with 
activation of p38 MAPK module rather than ERK-1/2 module (Fig 3.21 and Fig. 
3.22). This preliminary finding was in line with recent findings of Mion and 
colleagues [80] which suggested the involvement of p38 MAPK module MAPK 
signaling pathway rather than ERK-1/2 module in induction of IL-10 production 
from TLR4- or TLR9-stimulated B cells. When the requirement of MEK-ERK 
signaling for induction of IL-10 production from Helicobacter-stimulated B cells 
was taken into consideration, these findings could be interpreted as utilization of 
differential intracellular signaling pathways in IL-10 induction depends on the type 
of ligand, therefore stimulated TLR.  
Significance of this research underlies in its contribution to the understanding of 
unexplored intrinsic signal transduction pathways of Helicobacter-activated IL-10+ B 
cell subset leading to IL-10 induction. B cells belong to a group of immune cells that 
are collectively called APCs along with macrophages and DCs which take active role 
in innate immune response. B cells are also important players of adaptive immune 
response along with T cells. B cells are unique that they resemble both APCs and T 
lymphocytes with their various characteristics. Common signaling pathway leading 
to IL-10 production pathway was found to be ERK module in previous studies [75]. 
Results of this work suggest involvement of ERK-1/2 module of MAPK pathway in 
IL-10 induction and secretion from Helicobacter-activated B cells (Fig. 4.1).  
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Figure 4.1: Proposed model of intracellular signaling pathway for IL-10 production 
from Helicobacter-activated B cells. Following investigation for 
activation status of specific kinases that take part in fundamental 
intracellular signaling pathways and monitoring the effect of chemical 
inhibitors which block relevant pathways on IL-10 secretion, ERK 
signaling module of MAPK pathway is found to be involved in 
induction of IL-10 production from Helicobacter-stimulated B cells 
rather than p38 MAPK signaling module of MAPK pathway, PI3K 
pathway or canonical pathway of NF-κB.       
This work has been performed only in protein level. Expression levels of IL-10 in 
mRNA level also need to be validated in order to determine a complete scheme for 
the role of designated intracellular pathways on IL-10 induction upon TLR2-
stimulation. The involvement of p38 MAPK and PI3K signaling pathways in 
Helicobacter-activated IL-10- B cells can also be investigated further. Moreover, the 
involvement of ERK-1/2 module of MAPK pathway on IL-10 production capacity 
and function of IL-10 Helicobacter-activated IL-10+ B cells can also be investigated. 
In conclusion, this study has contributed to the literature through providing 
molecular investigation of pathways regulating IL-10 production and describing the 
involvement of ERK-1/2 phosphorylation in IL-10 induction from Helicobacter-
activated B cells for the first time. 
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